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 PTEN (phosphatase and tensin homolog deleted on chromosome 10) is a lipid 
phosphatase that dephosphorylates PIP3 to PIP2, and negatively regulates the 
PI3K/AKT signaling pathway. PTEN is an essential tumor suppressor gene frequently 
deactivated in cancer cells. Previous work in our lab and by others has shed light on the 
regulation of PTEN by a cluster of phosphorylation sites within the C-terminal regulatory 
tail at residues Ser380, Thr382, Thr383 and Ser385. Tetra-phosphorylation of the C-
terminal tail binds to the C2 domain and leads to a closed conformation which inhibits 
PTEN’s lipid phosphatase activity and membrane association, but increases its stability. 
We continued to investigate the molecular mechanisms of this regulatory mechanism 
using native chemical ligation. Systematic evaluation of the PTEN C-tail phospho-cluster 
showed that the conformational closure and autoinhibition was influenced by the 
aggregate effect of multiple phospho-sites rather than dominated by a single 
phosphorylation site. The photo-crosslinking results suggested that the phosphorylated 
C-tail not only interacts with the C2 domain but also the N-terminal phosphatase domain. 
The ubiquitination assays analyzing PTEN ubiquitination by WWP2 showed that PTEN 
C-tail phosphorylation could inhibit its ubiquitination by the HECT E3 ligases, 
presumably by disrupting the protein-protein interaction between PTEN and WWP2. 
 In the course of analyzing PTEN ubiquitination by WWP2, we noticed that the 
monomeric WWP2 is autoinhibited. WWP2 is a member of the NEDD4 HECT E3 ligase 
family, and the autoinhibition mechanisms of this family have been reported as involving 
intramolecular interactions between C2 or WW domains with the corresponding catalytic 
HECT domains. However, we found unexpectedly that a peptide linker tethering WW 




structural, and cellular analyses have revealed that the linker can lock the HECT domain 
in an inactive conformation and block the proposed allosteric ubiquitin binding site. Such 
linker mediated autoinhibition can be relieved by linker post-translational modifications, 
but complete removal of the linker can induce hyperactive autoubiquitination and E3 self-
destruction. We further showed that this regulatory mechanism is not limited to WWP2, 
but also applies to the related HECT family members WWP1, ITCH, and NEDD4-1.  
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Chapter 1: Introduction 
 
1.1 Post-translational Modifications 
While genes keep and encode the genetic information of life, proteins are the 
executor of most biological functions. Millions of different protein molecules with various 
sizes, shapes, structures and functions working together inside and outside of the cell 
contribute to the well-being of a normal healthy organism. Not only do the proteins have 
to function proficiently, they also have to adjust their activity precisely in response to 
different environment stimuli to support biological processes such as cell growth, 
proliferation, death, differentiation. As new functional groups in the side-chain or 
terminus of proteins, post-translational modifications expand the chemical repertoire of 
the 20 natural amino acids utilized by cells.(1, 2) The most common post-translational 
modifications include phosphorylation, ubiquitination, acetylation, glycosylation and 
methylation.(3) Attachment of these groups to the protein can change the size and 
charge of the unmodified protein and confer alterations in protein conformation, protein-
protein interactions, and enzymatic activity.(3, 4) Post-translational modifications, as the 
fundamental character of cell signal transduction, mediates almost all biological 
processes, and establishes the precise communication within cells.(5)  
Determining the mechanisms of how post-translational modifications are 
regulated represent an exciting area of research. In many cases, the enzymes that 
catalyze protein post-translational modifications are also regulated by post-translational 
modifications catalyzed by other enzymes, forming cascading pathways and inducing 
cross-talk among distinct post-translational modifications.(4, 6)  
1.2 PTEN Phosphorylation and Ubiquitination 
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  PTEN (Phosphatase and Tensin Homolog deleted on chromosome 10) is a lipid 
phosphatase that hydrolyzes phosphatidylinositol 3,4,5-triphosphate (PIP3), converting it 
to phosphatidylinositol 4.5-diphosphate (PIP2).(Figure 1)(7, 8) PIP3 is the key second 
messenger in the PI3 kinase-Akt signaling pathway.(9) The activation of Akt by PIP3 
induces multiple downstream signaling events, including promotion of cell proliferation, 
growth and survival, and the PI3K-Akt pathway is often perturbed in human cancer.(8) 
PTEN, is the best defined negative regulator of PI3K-Akt pathway that suppresses 
carcinogenesis.(10, 11) PTEN is the second most frequently-mutated gene in cancer, 
and the activity of PTEN is down-regulated in many types of cancer, such as prostate 
cancer, breast cancer, glioblastoma, and lung cancer.(12, 13) Down-regulation of PIP3 
inhibits the activation of Akt, thus arresting cell proliferation. Beyond its lipid 
phosphatase activity to counteract PI3K action, PTEN protein-protein interactions may 
also play roles in its anti-tumor activity.(14, 15)  
Human PTEN is a protein that is composed of 403 amino acids and its architecture 
consists of three major domains, an N-terminal phosphatase domain, a central C2 
domain, and a regulatory C-terminal domain (C-tail). A crystal structure of PTEN solved 
in 1999 uncovered detailed structural information about the phosphatase domain and C2 
domain.(16) The phosphatase domain (residues 15-186) contains the catalytic residue 
signature motif CxxGxR. C124 is a nucleophilic catalyst in the PTEN reaction. Although 
in the tyrosine phosphatase family, the PTEN structure is different from typical protein 
tyrosine phosphatases in that its catalytic pocket is much larger and can accommodate 
the larger phospholipid substrate. The C2 domain (residues 187-351) is involved in 
membrane binding. A loop enriched in lysines called the CBR III loop within the C2 









Figure 1: The PI3K/PTEN/AKT signaling pathway. In response to ligand binding (such as growth factor and 
hormones), receptor tyrosine kinases (RTKs) dimerize, stimulating their kinase activity and 
autophosphorylation. The phosphorylated tyrosine(s) within RTKs recruits PI3K through binding to the p85 
subunit that contains an SH3 domain. While recruited to the plasma membrane, PI3K phosphorylates the 
lipid PI(4,5)P2, generating PI(3,4,5)P3. PIP3 acts as a second messenger to recruit PDK and AKT to the 
plasma membrane, where AKT is phosphorylated and activated. The activated AKT phosphorylates 
downstream targets which promote cell proliferation, cell survival, glycolysis and resistance to apoptosis. 







(residues 352-403) is a regulatory domain that is highly negatively charged and subject 
to several post-translational modifications. Although it is widely accepted that the PTEN 
C-tail has a critical regulatory role, the solved PTEN crystal structure lacked the 49 C-
terminal residues, presumably due to the C-tail's intrinsic flexibility.  
PTEN is highly post-translationally modified including by phosphorylation, acetylation, 
Cys oxidation, ubiquitination, and SUMOylation,(8, 17) The C-tail of PTEN is rich in 
serine/threonine residues and a number of these have been shown to be 
phosphorylated. These phosphorylation sites include S362, T366, S370, S380, T382, 
T383, S385, and S398,(8, 18) and the cluster of residues S380, T382, T383, S385, have 
been reported to regulate PTEN stability, activity and subcellular localization.(19-21) 
This cluster of serine/threonine residues is believed to be phosphorylated by casein 
kinase 2 (CK2) in sequential fashion, S385 followed by S380, and then T382/T383.(22, 
23) These phosphorylation events induce a conformational change in which the C-tail 
binds to the C2 domain of PTEN and this down-regulates the phosphatase activity and 
disrupts phospholipid binding, thus inhibiting the localization to plasma 
membrane.(Figure 2)(19) There are reports that C-tail phosphorylation also protects 
PTEN from proteasomal degradation. Phosphorylated PTEN has also been reported to 
inhibit its association within protein complexes relative to non-phosphorylated PTEN.(24) 
Phosphorylation on T383 is suggested to be critical for regulating cancer cell 
migration.(15) Thus the available evidence points to the importance of PTEN 
phosphorylation on S380, T382, T383, S385 and elucidating a more detailed structure of 
phospho-PTEN could provide key insights into the biology of PTEN and give guidance to 
new therapy for cancer and other diseases. 
Apart from phosphorylation, ubiquitination is another important post-translational 










Figure 2: Schematic showing the regulation of PTEN by C-tail phosphorylation. The nonphosphorylated C-
tail of PTEN is unstructured and does not interact with the core of the protein, and PTEN stays in the open 
conformation. This nonphosphorylated form of PTEN has high affinity for the plasma membrane and high 
enzyme activity. When PTEN is tetra-phosphorylated at residues Ser380, Thr382, Thr383 and Ser385, the 
phospho-C-tail binds to the C2 domain, rendering a closed conformation. This conformational change 




the PTEN gene, the loss of PTEN protein is attributed to ubiquitin-mediated 
degradation.(25) Several E3 ligases for PTEN have been discovered, including NEDD4-
1, WWP2 and XIAP.(26-28) NEDD4-1, a HECT family E3 ligase, was the first discovered 
E3 ligase to ubiquitylate PTEN promoting both poly- and mono-ubiquitination. Poly-
ubiquitination by NEDD4-1 is suggested to regulate PTEN stability through proteasomal 
degradation, while mono-ubiquitination on K13 and K289 is reported to enhance PTEN's 
localization into nucleus.(29, 30) However, there is a provocative study showing that 
mice or cells depleted of NEDD4-1 by knockout have unchanged PTEN stability or 
localization, arguing for the role of other E3 ligases involved in PTEN regulation.(26) 
WWP2 is another HECT E3 ligase for PTEN, regulating PTEN stability through poly-
ubiquitination.(27) Degradation of PTEN by WWP2 has been shown to be involved in 
melanoma development after UV exposure.(31) Another proposed E3 for PTEN, XIAP, 
is a Ring-finger family E3 ligase that regulates PTEN stability and nuclear localization by 
both mono- and poly-ubiquitination.(28) Since C-tail phosphorylation has been described 
to inhibit degradation, we hypothesize that this mechanism may involve phosphorylation 
mediated changes in the interactions among PTEN and E3 ligases. Biochemical and 
biophysical study into the details of non-phosphorylated and phosphorylated PTEN with 
E3 ligases could help better illuminate how PTEN is regulated by phosphorylation and 
ubiquitination.  
Beyond post-translational modifications, PTEN activity and stability is likely regulated by 
protein-protein interactions. PTEN has been reported to interact with MAGI-2, 
MAST1,2,3, DLG1, NHERF1,2, P85a, DJ1, Man2C1, Sharpin, PREX2a and Histone 
H1.(14, 32-41) Membrane associated guanylate kinase inverted-2 (MAGI-2) is an 
adherens junction scaffold protein. PTEN has been reported to bind to MAGI-2 via an 
interaction between the C-terminal PDZ binding motif of PTEN and a second PDZ 
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domain of MAGI-2, thus enhancing PTEN stability and activity.(32) This interaction may 
inhibit cancer cell migration and proliferation.(42) PTEN-MAGI-1 interaction is proposed 
to be potentiated by PTEN C-tail phosphorylation at T382/T383.(43) Other proteins 
interacting with PTEN through its PDZ domain are microtubule-associated S and T 
kinases 1, 2, and 3 (MAST1,-2, and -3), discs large (DLG), and Na+/H+ exchanger 
regulatory factors 1 and 2 (NHERF1,and 2).(8) Another interesting protein interacting 
with PTEN is p85a, the subunit of PI3K. Although PI3K functionally opposes PTEN, its 
subunit p85a is suggested, paradoxically, to bind and activate PTEN directly, with a 
preference for binding non-phosphorylated PTEN.(36, 44) Phosphatidylinositol 3,4,5-
triphosphate RAC exchanger 2a (pREX2a) is also suggested to interact with PTEN and 
inhibit PTEN's activity.(41) Interestingly, the binding of non-phosphorylated and 
phosphorylated PTEN (S380, T382, T383) with pREX2a was reported to be similar, but 
pREX2a was stated to only inhibit the activity of phosphorylated PTEN. This was 
rationalized by implicating the PH domain of pREX2a binding the PTEN phosphorylated 
C-tail, releasing it from autoinhibition.(40)  
 
1.3 Ubiquitin and Ubiquitination 
 Ubiquitin is a small regulatory protein containing 76 amino acid residues (~8.5 
kDa). The discovery of ubiquitin dates back to 1975 when Gideon Goldstein and co-
workers isolated the ‘ubiquitous immunopoietic polypeptide’ from a variety of eukaryotic 
cells.(45) This protein was found to express ubiquitously in all tissues of eukaryotic 
organisms and thus given the name ‘ubiquitin’. The sequence of ubiquitin is highly 
conserved among all eukaryotic cells. As an abundant protein, the concentration of 
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ubiquitin in the cell is estimated to be 10 to 30 µM.(46) In the human genome, ubiquitin is 
expressed by four genes including UBB, UBC, UBA52 and RPS27A.(47) 
Ubiquitin is a tiny globular protein that has the β-grasp fold, featured by a core 
structure consisting of beta(2)-alpha-beta(2) (two β-strands followed by an α-helix and 
then two β-strands).(Figure 3A)(48-50) The overall structure of ubiquitin is extremely 
compact and tightly hydrogen-bonded. Nearly 90% of the polypeptide chain is involved 
in the hydrogen-bonding of in its secondary structure, and there is a remarkable 
hydrophobic core formed between the β-strands and the α-helix. These structural 
features make ubiquitin a highly stable protein. Even after treatment under denaturing 
conditions, ubiquitin can spontaneously and efficiently fold back to its native 
conformation. Compared to the core structure, the C-terminal tail of ubiquitin is relatively 
labile. However, the di-glycine at the C-terminus is a key feature of ubiquitin for its 
function. 
 Ubiquitin's role is to serve as a very large PTM that is added to substrate 
proteins, the process of which is called ubiquitination or ubiquitylation. To be more 
specific, through a ubiquitination reaction, the C-terminal carboxyl group of ubiquitin is 
conjugated to the amine sidechain of a lysine in substrate protein, forming an isopeptide 
bond, so that ubiquitin is covalently attached to the substrate protein.(51) Ubiquitination, 
like phosphorylation, is a fundamental post-translational modification essential for protein 
function and signal transduction. There are numerous forms of ubiquitination including 
monoubiquitination and polyubiquitination, and they affect substrate proteins in many 
different ways such as providing marking for proteosomal degradation, altering sub-
cellular localization, changing its catalytic activity, and regulating protein-protein 






Figure 3: (A) Structure of ubiquitin and different types of ubiquitination. The crystal structure of ubiquitin 
shows the typical beta(2)-alpha-beta(2). The lysine residues and the first methionine are labeled as they are 
the site where poly-ubiquitin chains form. Different forms of ubiquitination include mono/multi-mono, poly 
and branched ubiquitination, each carrying different biological functions. (B) The process of ubiquitination 
reaction. E1 utilizes ATP to charge ubiquitin to the catalytic cysteine, forming a thioester bond. E1~Ub then 
transfers the ubiquitin to the catalytic cysteine of E2. With the help of E3, the ubiquitin is transferred from E2 






 Monoubiquitination is the addition of one ubiquitin molecule to one lysine of the 
substrate protein. Multi-monoubiquitination can also occur in which there is addition of 
one ubiquitin to multiple lysine residues in the same substrate protein.(Figure 3A)(50) 
Monoubiquitination has been shown to play a role in DNA repair, transcription, trafficking 
and endocytosis.(29, 52-55)  
  Different from monoubiquitination, polyubiquitination involves the formation of a 
chain of ubiquitins attached to a single lysine residue of a substrate protein. In ubiquitin, 
the 7 lysine residues (K6, K11, K27, K29, K33, K48, K63) and the amino terminus 
provide eight attachment points where ubiquitin molecules can be added. (Figure 3A) 
(50, 52) After monoubiqutination, additional ubiquitins are added to the initial (proximal) 
ubiquitin to produce a polyubiquitin chain. Depending on which lysine the new ubiquitin 
is conjugated to, there are numerous forms of polyubiquitin chains. The most common 
are K48- and K63-polyubiquitination.(52)  
 Ubiquitination conjugation is a complicated process involving multiple steps and 
enzymes. (Figure 3B) (50, 51) There are three types of enzymes: ubiquitin activating 
enzyme E1, ubiquitin conjugating enzyme E2, and ubiquitin transferase E3. The overall 
ubiquitination scheme consists of three steps:  
1. Activation. The activation of ubiquitin involves one molecule ubiquitin as the 
substrate, MgATP as the energy source, and E1 ubiquitin activating enzyme 
as the catalyst. In the human genome, there are only two E1s, but this step is 
an efficient reaction and very fast.(56) First, the E1 binds both ATP and 
ubiquitin, and catalyzes the acyl-adenylation of the C-terminus of ubiquitin, 
producing a ubiquitin-adenylate intermediate. The C-terminal di-glycine is a 
key feature for E1 recognition and further processing. Next, the sulfhydryl 
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group from the active site cysteine of the same E1 attacks the ubiquitin-
adenylate to form a thioester bond, resulting in covalent attachment of 
ubiquitin to the active site cysteine of the E1 and release of AMP.  
2. Conjugation. In this step, activated ubiquitin gets transferred to the active site 
cysteine on the ubiquitin conjugating enzyme E2. About 35 different E2s have 
been characterized in the human genome.(57) During the conjugation 
reaction, E2 binds to E1 and the ubiquitin on the active site of E1 undergoes 
a transthioesterification reaction to switch the ubiquitin to a Cys on the E2.  
3. Ligation. In the ligation step, ubiquitin is transferred from the E2 Cys thioester 
species to the lysine residue of the substrate protein. This is facilitated by 
participation of E3 ubiquitin ligases which bind the substrate protein and 
E2~ubiquitin thioester to enable the formation of an isopeptide bond between 
the C-terminal carboxyl of ubiquitin and the amine group of a lysine sidechain 
of the substrate. E3s function as the substrate recognition module in the 
ubiquitination cascade. To ensure specificity, there are more than 600 E3s to 
target a different set of substrate proteins for ubiquitination.(58) The E3s also 
work together with a particular E2 and other regulators to coordinate the 
conjugation of specific ubiquitin linkages onto substrates.  
The identified E3 ligases can be categorized into three major classes: RING 
(really interesting new gene), HECT (homologous to E6AP C-terminus) and RBR (RING-
between-RING).(50) RING E3 ligases catalyze ubiquitination by stimulating the direct 
transfer of ubiquitin from E2~ubiquitin to substrate. HECT and RBR are different in that 
they contain a catalytic cysteine which receives ubiquitin from E2~ubiquitin and transfers 
to substrate protein subsequently. Compared to RING, HECT and RBR are more 
classical enzymes which are directly involved in the chemical reaction of ubiquitination.  
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RING E3s, characterized by the presence of a RING domain, are the largest E3 
family and contain about 600 members.(59) The RING domain is the functional domain 
in a RING E3 ligase that recruits E2~ubiquitin and facilitates ubiquitin transfer. The 
structure of a RING domain contains two zinc ions coordinated by cysteines and 
histidines, which are essential for the correct folding of the domain. With the RING 
domain as a common feature, the large number of RING E3 family members show great 
diversity in biochemical and biophysical properties. There are RING E3s that are 
monomeric, homodimeric, heterodimeric and multi-subunit, and there are also RING E3s 
that exist as a subunit of a large complex consisting of many protein components.(50)  
HECT E3s are a family of E3 ligases with 28 members in human. They all 
contain a HECT domain that uses a cysteine to receive ubiquitin from E2 and transfer to 
substrate.(60) The characteristics of HECT E3s will be discussed in detail in the 
following sections.  
 RBR E3 ligases share the structural feature of a RING1-IBR-RING2 domain 
combination: two RING domains with a IBR domain in between.(50) In the human 
genome, there are 14 known RBR E3 members, among which PARKIN and HHARI 
have drawn great interest.(61-63) RBR E3s, although structurally similar to RING E3s as 
they both contain the zinc binding RING domains, have distinctive enzyme mechanisms. 
RBR E3s do not function just as a template that brings E2~ubiquitin and substrate 
protein together; rather, they contain a catalytic cysteine that forms a thioester 
intermediate which allows for transfer of ubiquitin to protein substrate.(62) In this sense, 
RBR E3s follow a catalytic mechanism that resembles that of HECT E3. The catalytic 
cysteine in the RING2 domain receives ubiquitin from E2~ubiquitin that also involves 
recruitment by RING1 domain, and then transfers ubiquitin to the protein substrate.(62) 
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Structurally like RING E3s and functionally like HECT E3s, RBR E3s are an interesting 
composite family of ubiquitin ligases. 
 
1.4 Overview of HECT E3 Ubiquitin Ligases 
 HECT E3 ubiquitin ligases, as introduced above, are a family of 28 members in 
human.(50) In general, they are comprised of an N-terminal substrate-binding domain 
and a C-terminal HECT domain. Based on different types of N-terminal domains, the 
HECT E3s can be categorized into three classes: the NEDD4 family (9 members), which 
contain WW domains that recognize Pro/Tyr motifs in substrate proteins; the HERC 
family members (6 proteins), which possess RCC1 (regulator of chromosome 
condensation-1)-like domains (RLD) and include large HERCs (>500 kDa) with multiple 
RLDs and small HERCs (~100 kDa) with a single RLD; and single HECT E3s (13 
members) that have neither WW nor RCC1 domains.(64)  
 The HECT domain is the catalytic domain of HECT E3 ligases and is quite 
structurally conserved among all HECT family members.(60) In general, the HECT 
domain contains about 350 residues which are divided into a large N-lobe (~240 
residues) and a small C-lobe (~110 residues) connected by a hinge loop. (Figure 4A) 
(50, 65) The N-lobe contains the E2 binding region, the protein substrate binding region, 
and a non-covalent ubiquitin binding site (exosite).(66-69) The C-lobe contains the 
catalytic cysteine which receives and transfers ubiquitin to protein substrates. The hinge 
loop which is a flexible linker between the N- and C-lobe plays a key role in the 
conformational dynamics of the HECT domain. (Figure 4A) (50, 65) In different 
orientations of the C-lobe relative to the N-lobe, the HECT domain can adopt two 














Figure 4: (A) Crystal structure of a HECT domain in the T-shape. HECT domain consists of a large N-lobe 
(orange) and a C-lobe (magenta), connected by a flexible linker called the hinge loop. The catalytic cysteine 
is located within the C-lobe, and the N-lobe contains the E2 binding region, the substrate binding region and 
a ubiquitin allosteric binding site (exosite). (B) The structure of a HECT domain in the L-shape. (C) The 
catalysis process of a HECT enzyme. The hinge loop is flexible so the HECT domain can freely switch from 
T to L-shape. When E2~Ub binds to the E2 binding region, the HECT domain stays in the T-shape 
conformation so the catalytic cysteine is close to the E2 binding region and receives the ubiquitin from E2. 







 This conformational flexibility allows the C-lobe to receive ubiquitin from the charged E2 
protein and transfer it to the protein substrate. Studies have shown that hinge loop 
truncations or proline mutation disrupt the ubiquitin transferase activity of the HECT 
domain.(65)  
 The mechanism of HECT E3’s catalytic function involves at least four stages: 
first, recruitment of E2~ubiquitin; second, transthioesterification to the catalytic cysteine 
in the C-lobe to form a HECT~ubiquitin thioester intermediate; third, transferring ubiquitin 
to the lysine of a substrate; fourth, adding multiple ubiquitin molecules to form poly-
ubiquitin chains. (Figure 4C) (50) The E2 binding region at the N-lobe of the HECT 
domain forms a groove structure comprised of two β-strands and a connecting coil.(66) 
The loop between the α-helix and β-strand at the N-terminus of an E2 interacts with the 
hydrophobic groove of the E2 binding region within the HECT domain to stabilize the E2-
E3 interaction. Hydrophobic residues especially a phenylalanine in the E2 N-terminus is 
critical and the HECT interacting E2s, such as UbCH7, UbCH5B and UbCH5C, all 
contain this phenylalanine.(70) There are several hydrogen bonds between the ubiquitin 
and the HECT N- and C-lobe interface that position the C-terminus of ubiquitin in an 
extended conformation and are proposed to activate the thioester.(66, 71) Transfer of 
ubiquitin from the cysteine of E2 to that of E3 is triggered by the rotation of the hinge 
loop which changes the position of the E3 cysteine and allows for 
transthioesterification.(50) Subsequently, the ubiquitin is transferred to substrate with a 
dramatic rotation of the hinge loop which brings the ubiquitin to the substrate binding 
region on the other side of HECT N-lobe.(67)  
 In addition to the functional motifs such as the E2 binding region, the catalytic 
cysteine, the hinge loop and substrate binding region, there are two important structural 
features in the HECT domain including its non-covalent ubiquitin binding region (Figure 
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4A)(68, 72-74) and the last five residues of the C-tail(71, 75).  The non-covalent binding 
site, also called the exosite, is located between the E2 binding region and the protein 
substrate binding region in the N-lobe.(73) Distinct from the transferred ubiquitin 
covalently attached to the catalytic cysteine and located at the interface of the N- and C-
lobes, ubiquitin also binds to the exosite non-covalently. The function of the exosite still 
remains a question. When first discovered in Rsp5 (homolog to NEDD4-1 in yeast) using 
NMR, the function of the non-covalent ubiquitin binding was thought to limit the length of 
polyubiquitin chain.(74) However, an alternative mechanism was suggested by 
biochemical and structural studies of SMURF2 and NEDD4-1.(72, 73) The crystal 
structure of HECT~ubiquitin in complex with an additional ubiquitin bound at the exosite 
showed that the non-covalent ubiquitin might contribute its lysine (K63) as a receiver of 
the Cys-thioester linked ubiquitin to form polyubiquitin chains.(73) Mutation of key 
interacting residues at the exosite that disrupt the binding of ubiquitin to the exosite 
resulted in products with shorter polyubiquitin chains.(73) However, a recent study using 
an engineered ubiquitin variant which targets the exosite with high affinity indicated an 
allosteric activating role of exosite ubiquitin binding.(69) In WWP1/WWP2/ITCH, the 
engineered ubiquitin variants were shown by crystal structures to bind to the exosite just 
like wild-type, and they dramatically activated the ubiquitin transferase activity of the 
HECT E3.(69) Although it still remains unknown whether non-covalent ubiquitin binding 
site exists in every member of the HECT E3 family, and what is its exact role for E3 
regulation, this site seems to be a promising target for developing small molecules to 
modulate HECT activity.(76) 
Another interesting structural feature is the last five residues of the HECT 
domain. Although the last five residues show some variation among different HECT 
family members, two residues are highly conserved including a phenylalanine (F-4) and 
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a terminal acidic residue (E-1).(71, 75) Deleting the last five residues or mutating the key 
residues does not affect the transthioesterification between E2 and E3, but significantly 
blocks the ubiquitination of substrate, suggesting that these residues are involved in the 
step for transferring ubiquitin to the lysine of protein substrate.(67, 71) In many crystal 
structures of HECT domains, the last five residues are either deleted to allow 
crystallization or invisible(65, 71), whereas in the structure of a complex involving the 
Rsp5 WW3-HECT domain, ubiquitin and substrate peptide, which captures the step that 
ubiquitin is being transferred from HECT to the lysine of substrate, the electron density 
of F-4 was observed(67). The structure depicts the HECT domain in the L-shape 
conformation such that the C-lobe is rotated into a location near the substrate binding 
region. F-4 binds to the N-lobe through hydrophobic interaction with another 
phenylalanine (F505) and a leucine (L506) within the N-lobe at the interface between the 
N- and C-lobes. Although F-4 mutation to leucine abolishes ubiquitination catalysis, a 
complementary substitution of L506 to phenylalanine or tryptophan could rescue the 
activity.(67) These results suggest that the role of F-4 is to stabilize the L-shape 
conformation by anchoring the N- and C-lobe in an orientation which is suitable for 
ubiquitin transfer to substrate. However, the role of E-1 is uncertain based on current 
structural studies, where it has not been visualized. It was hypothesized that E-1 might 
be crucial for positioning or activating the incoming lysine of the ubiquitin acceptor.(71) 
Indirect evidence points to an active site positioning of E-1, since E-1 replacement with a 
lysine (K-1) leads to ubiquitin conjugation to K-1.(71) 
 Although HECT E3s share a common catalytic domain, the various family 
members are proposed to have specific substrates and distinct functions.(64) They 
control numerous cellular processes including protein degradation, endocytosis, sorting 
and trafficking of transmembrane proteins and play important roles in a variety of 
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physiological and pathological conditions.(27, 60, 64, 77-84) E6AP (E6 associated 
protein), which belongs to the single HECT E3s, was the first HECT E3 identified.(85) 
When associated with E6 protein, the viral oncoprotein expressed by human papilloma 
virus (HPV), E6AP can target p53 for ubiquitination and proteosomal degradation.(86) 
This is a fundamental mechanism for HPV-mediated oncogenesis. Other important 
single HECT E3s include EDD, HUWE1 and HACE1 which are involved in cancer and 
neurodevelopment.(87-89) The large HERC protein HERC1 and HERC2 possess 
phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2)-dependent guanine nucleotide-
releasing factor (GRF) activity(90), and are proposed to be involved in membrane 
protein trafficking, as well as regulate cell size and growth through the mTORC1 
pathway(91). The small HERC proteins do not have GRF activity and their function has 
been less studied. The small HERCs are reported to regulate intracellular vesicle 
transport and are also stated to have roles in spermatogenesis, immune response and 
other physiological processes.(92-96) The NEDD4 family HECT E3s are the most 
intensively studied HECT enzymes and are the focus of my thesis work, the function of 
which will be described later.  
 
1.5 Overview of NEDD4 family  
 The NEDD4 family of HECT E3 ligases are characterized by an N-terminal C2 
domain, two to four WW domains and a C-terminal HECT domain.(50) The C2 domain is 
a phospholipid binding domain and can target the E3 to the plasma membrane, 
endosomes or other proteins.(97) The WW domains recognize and bind to PY (Pro/Tyr) 
motifs in substrate proteins.(98, 99) They have a preference for PPxY sequences and 
can also bind to LPxY and other PY motifs.(100) Some WW domains bind to 
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phosphorylated Ser/Thr, often triggering ubiquitination of phosphorylated proteins.(101) 
The WW domains are small structural units containing about 30 amino acid residues, 
and the structure usually comprises two to three parallel β-strands.(99, 102) Although 
their sequences and structures are conserved, distinct WW domains show variable 
affinities for different substrates.(99)  
The NEDD4 family members play diverse roles in all eukaryotic organisms from 
yeast to mammals. In yeast, Rsp5 is the only NEDD4 family member and is an essential 
gene.(103) Proposed cellular functions of Rsp5 include chromatin remodeling, regulation 
of transcription by binding to the large subunit of RNA polymerase II, mitochondrial 
inheritance, regulation of endocytosis, and sorting of a variety of transmembrane 
proteins, transporters and receptors.(103-106) Caenorhabditis elegans WWP1 
(ceWWP1) is essential for late stage embryogenesis of these worms.(107) ceWWP1 has 
been shown to target RNA polymerase II for ubiquitination and degradation, as well as 
LIN-12 to suppress the Notch signaling pathway.(108, 109) Drosophila melanogaster 
has three NEDD4 family members including NEDD4, ITCH and SMURF, which also act 
as suppressors of the Notch pathway.(110)  
In mammalian cells, there are 9 NEDD4 family members which can be divided 
into four sub-families: NEDD4-1 and NEDD4-2; SMURF1 and SMURF2; HECW1 and 
HECW2; WWP1/WWP2/ITCH.(64) Each sub-family shares relatively high sequence 
conservation. The NEDD4 family HECT E3 ligases play diverse roles in regulating 
transcription by ubiquitinating key transcription factors, leading to proteasomal 
degradation.(60, 64) For example, WWP1 has been suggested to target the transcription 
factor p53, one of the most important tumor suppressors, for degradation(111); WWP2 
has been shown to ubiquitinate OCT4, a key transcription factor in embryonic stem cell 
development and differentiation(78). NEDD4 E3 ligases also target many important 
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signaling proteins for ubiquitination inducing proteasomal degradation or altered 
trafficking, thus influencing many signal transduction pathways. PTEN, a negative 
regulator in the PI3K/AKT signaling pathway, is ubiquitinated by WWP2 and NEDD4-
1.(27, 30) Poly-ubiquitination of PTEN by WWP2 or NEDD4-1 leads to proteasomal 
degradation of PTEN and activation of downstream AKT signaling, while mono-
ubiquitination of PTEN by NEDD4-1 leads to nuclear localization.(30) Several 
transmembrane proteins including growth factor receptors and ion channels have been 
suggested to be substrates of different NEDD4 E3 ligases. For instance, NEDD4-1 
ubiquitinates insulin-like growth factor 1 receptor (IGF1R), epidermal growth factor 
receptor (EGFR) and fibroblast growth factor receptor (FGFR)(112-114); SMURF1 and 
SMURF2 negatively regulates the TGFβ pathway by ubiquitinating the TGFβ receptor as 
well as the downstream Smads and TGFβ-responsive transcription factors(115-117); ion 
channels such as epithelial Na+ channel (ENaC) is targeted by NEDD4-1, NEDD4-2 and 
WWP2 for degradation.(118-121)  
Mammalian NEDD4 family members have important roles in numerous 
physiological processes and are involved in many diseases.(60, 64, 106) A number of 
the NEDD4 family members are identified as vital regulators of development and 
differentiation.(106) WWP2 is highly expressed in embryonic stem cells (ESC) and its 
level decreases as the stem cell differentiates into different tissues.(78) WWP2 targets 
OCT4 and RNA polymerase II large subunit in ESC for ubiquitination and degradation, 
and regulation of WWP2 activity could potentially determine the fate of the ESC.(122, 
123) NEDD4-1, NEDD4-2 and HECW2 have also been shown to regulate the 
development of neural tissue, intestine and muscle(124-126), and SMURF1 and 
SMURF2 are essential regulators of bone tissue development(115, 117, 127, 128). The 
immune system is regulated by NEDD4 family members as well. ITCH E3 ligase is an 
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essential molecule for the development and differentiation of regulatory T cells, the 
knocking out of which leads to defects in T helper 2 (TH2) cells, increased levels of IL-4, 
IL-5, IgE and IgG.(129, 130) The phenotype of loss of ITCH function includes pruritis and 
several autoimmunity syndromes. The molecular mechanism of ITCH function includes 
the observation that ITCH can target JUNB, the transcription factor for IL4 gene 
expression, for ubiquitination and proteasomal degradation.(131, 132) There are a large 
number of studies that link NEDD4 E3 ligases to cancer.(60) Several important cancer 
related proteins are regulated by NEDD4 E3s including PTEN, p53, and Notch1.(27, 29, 
30, 111, 133) NEDD4 E3 members are suggested to be oncogenes and can promote the 
progression of cancer.(60) However, accumulating evidence indicates that many NEDD4 
E3 ligases, while thought to be oncoproteins, also carry tumor suppressor 
properties.(134-136) These seemingly contradictory functions indicate that the roles of 
NEDD4 E3s in cancer are complicated and the regulation of NEDD4 E3 under different 
conditions or in different cell types could can spark distinct biological outputs. 
  
1.6 Regulation of NEDD4 HECT E3 Ligases 
 Because of their biomedical importance and direct involvement in the catalysis of 
protein ubiquitination, the enzymatic activities of NEDD4 HECT E3 ligases need to be 
tightly regulated to ensure normal function and prevent pathogenesis. The C-terminal 
catalytic HECT domain is autoinhibited through intramolecular interactions with other 
domains, and can be regulated by posttranslational modifications, 
dimerization/oligomerization and protein-protein interactions.(50) 
Most of the intramolecular interactions within NEDD4 HECT E3s are reported to 
autoinhibit, preventing hyperactivation. The C2 domain has been shown to be the 
22 
 
autoinhibitory domain for Smurf2 and NEDD4-1.(137, 138) NMR studies showed that the 
C2 domain binds to the region near catalytic cysteine in the HECT C-lobe, as well as 
interfering with the ubiquitin exosite, thus blocking the transthioesterification 
reaction.(137, 138) It has been suggested that WW domains mediate the autoinhibition 
of NEDD4-2 and ITCH.(100, 139) One proposal is that WW domains bind to the LPXY 
motifs in the HECT domains and inhibit catalytic activity. Competitive binding of 
substrate proteins containing PPXY motifs to WW domains could release the 
autoinhibited HECT and activate the enzyme.(100) In addition, a proline rich region 
(PRR) between the C2 domain and the first WW domain was proposed to be an 
autoinhibitory motif by binding to the HECT domain.(139)  
The autoinhibited NEDD4 E3 ligases can be activated by different post-
translational modifications in a variety of ways. In NEDD4-1, several tyrosine 
phosphorylation sites have been identified and characterized, including Tyr43 in the C2 
domain and Tyr585 in the HECT domain.(140) It is proposed that phosphorylation at 
these two sites could disrupt the autoinhibitory interaction between the C2 domain and 
the HECT domain, thus activating NEDD4-1 activity.(140) ITCH is phosphorylated at 
Ser199, Ser232 and Thr222 within the PRR, catalyzed by JNK1.(77, 141) This 
phosphorylation event is suggested to lead to a conformational change and activation of 
ITCH.(141) Tyr371, phosphorylated by FYN, in the linker region between WW2 and 
WW3 domain was proposed to inhibit ITCH activity.(142) The Ser444 of NEDD4-2 is a 
target of AKT1 and SGK1 for phosphorylation upon activation by hormones such as 
insulin and aldosterone.(143-145) Unlike NEDD4-1 or ITCH, which are proposed to be 
directly activated by phosphorylation events, phospho-NEDD4-2 is suggested to recruit 
14-3-3, an accessory protein that facilitates the binding of NEDD4-2 to its substrate 
ENaC.(146) In addition to phosphorylation, NEDD4 HECT E3s are also regulated by 
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other posttranslational modifications such as arginine methylation which regulates 
Smurf2 stability(147) and lysine neddylation which promotes Smurf2 degradation and 
increase Smurf1 activity(148).  
Dimerization/oligomerization has been shown to regulate HECT E3 ligase 
activity, but the underlying mechanisms still remain elusive and the conclusions are 
controversial. It was observed that dimerization/oligomerization of WWP2 leads to 
inhibition of ubiquitin transferase activity through a trans interaction between the C2 
domain of one WWP2 and the HECT domain of the other WWP2 molecule.(149) 
NEDD4-1 has also been demonstrated to be regulated by oligomerization. A potential 
trimerization interface within the HECT domain is blocked by the α1-helix of the HECT 
domain, and upon ubiquitination of the lysine residue located in the α1-helix, the 
trimerization interface is exposed and this ubiquitination-dependent trimerization process 
inhibits the E3 ligase activity of NEDD4-1.(150) A recent structural study revealed that 
HUWE1, another HECT family member, is autoinhibited through dimerization, and 
disruption of the dimerization interface activates the enzyme.(151) However, it still 
remains elusive and controversial how dimerization/oligomerization regulates the activity 
of HECT E3 ligases. Although the studies mentioned above indicate inhibitory role of 
dimerization/oligomerization, contradictory results were observed for E6AP.(152) It was 
found that the active form of E6AP is trimeric.  
 Intermolecular protein-protein interactions are another regulatory mechanism 
critical for of NEDD4 HECT E3s. SMAD7 acts as an important activator for Smurf2, 
which antagonizes the intramolecular interaction between the C2 and HECT domains, 
relieving autoinhibition.(137, 153) SMAD7 also allosterically activates Smurf2 by 
enhancing the affinity of Smurf2 HECT domain for E2 binding.(153) NDFIP1 and 
NDFIP2 are transmembrane proteins that serve as adaptor proteins for NEDD4 family 
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members including NEDD4-1, ITCH and WWP2.(154) NDFIP1 and NDFIP2 contain 
three proline rich motifs that bind WW domains of NEDD4 E3s, and NDFIP1 and 
NDFIP2 can impact the subcellular localization and activity of NEDD4 E3s.(139) Smurf1 
was demonstrated to interact specifically with casein kinase 2-interacting protein 1 
(CKIP1) through its linker region between WW domains, and this interaction was shown 
to enhance substrate recognition and catalytic activity.(155) Protein-protein interactions 
regulate not only the activity but also the type of NEDD4-mediated ubiquitination. 
NEDD4-1 regulation by p34 is an example. p34 binds to the WW1 domain of NEDD4-1 
and is suggested to augment its ubiquitination activity.(156) Overexpression of p34 
promotes NEDD4-1-catalyzed polyubiquitination of protein substrate while knocking 
down of p34 leads to mostly monoubiquitination.(156)   
 
1.7 Expressed protein ligation 
 Expressed protein ligation is a chemical ligation technique that allows for ligation 
of a synthetic peptide and purified recombinant protein resulting in a semi-synthetic 
protein.(157, 158) There are two major approaches to do expressed protein ligation: C-
terminal expressed protein ligation where the protein with C-terminal thioester is ligated 
with peptide with N-terminal cysteine (Figure 5A)(158), and N-terminal expressed protein 
ligation where the synthetic peptide with C-terminal thioester is ligated with protein that 
has a N-terminal cysteine (Figure 5B)(159).  
C-terminal expressed protein ligation is the more classical and widely used 
approach. This technique introduces a thioester at the C-terminus of the protein taking 










Figure 5: (A) Schematic showing the C-terminal native chemical ligation. (B) Schematic showing the N-







bacteria and yeast that can splice themselves out from two flanking polypeptide chains 
while ligating the two chains together.(160) This process is analogous to intron/exon 
splicing in RNA. The inteins used in expressed protein ligation have been engineered so 
that they can by trapped in the first step of splicing.(158) In this thesis, the technique is 
utilized to make semi-synthetic PTEN with different C-terminal phosphorylations, as well 
as unnatural amino acid residues such as benzoylphenylalanine (BPA) and biotinylated 
lysine for crosslinking studies. In our studies, we employ truncated versions of PTEN 
fused with intein at the C-terminus, followed by a small chitin binding domain.(19) 
Recombinant fusion protein is purified using chitin resin. The junction site between 
PTEN and the intein exists in an equilibrium between a native amide bond and an intein 
catalyzed thioester rearrangement. Using thiol reagent such as 
mercaptoethanesulfonate (MESNA), the transient thioester bond at C-terminus of PTEN 
can be trapped, and the intein is cleaved producing PTEN with C-terminal MESNA 
thioester. The purified PTEN-thioester can subsequently react with the N-terminal 
cysteine on the peptide. The cysteine on the peptide acts as a nucleophile to displace 
the MESNA thioester, and the peptide thioester undergoes a rearrangement to yield a 
native amide bond at the ligation site. In this way, the full-length semisynthetic PTEN is 
generated containing recombinantly expressed and synthetic parts. The synthetic 
peptide is naturally incorporated into the PTEN protein which carries site-specific 
phosphorylation and unnatural amino acids.   
While the method mentioned above is efficient for introducing modifications on 
the C-terminus of the protein, N-terminal expressed protein ligation is an alternative way 
to ligate a peptide to a recombinant protein.(159) The basic concept is similar in that 
both techniques use the same chemoselective, cysteine-mediated ligation, but for N-
terminal expressed protein ligation the thioester is produced in the synthetic peptide. 
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This thioester synthetic peptide is ligated to a recombinant protein containing an N-
terminal Cys.  In this thesis, I use the N-terminal expressed protein ligation approach to 
make a semisynthetic WWP2 construct with tyrosine phosphorylation. The peptide with 
the C-terminal thioester can be synthesized using Dawson Dbz AM resin(159), and the 
recombinant protein with N-terminal cysteine can be generated using SUMO protease or 
TEV protease cleavage. The ligation produces a semisynthetic protein with site-specific 
modification at the N-terminus.  
Expressed protein ligation has been a powerful technique to install modifications 
on the N-terminus and C-terminus of proteins.(157) In this thesis work, this technique 
has been used to site-specifically install posttranslational modifications, as well as 
unnatural amino acids used for photo-crosslinking and crystallography. Not limited to 
these, expressed protein ligation can also be applied to introduce any modification that 
can be incorporated into a synthetic peptide such as fluorescent molecules, isotopic 
residues and other tags. The great advantage is that it allows for the exact positioning 
and stoichiometry of the intended modification. Despite many advantages, expressed 
protein ligation has its limitations.  Expressed protein ligation is best suited to study 
phosphorylation sites located at the N- or C-termini of a protein (or protein domain) of 
interest, to avoid multi-segment ligation.  Fortunately, phosphorylation sites are often 
near protein termini since they are usually located in flexible regions that tend to be at 
the ends of proteins or protein domains. In some cases, when flexible modified regions 
are far from the termini, circular permutation strategies can be employed to analyze 
PTMs.(161) Another potential limitation is the requirement of a cysteine at the ligation 
junction.  Since Cys is one of the least frequently encoded amino acids in proteins(162), 
introduction of a Cys by mutation is commonly required for the convenient use of the 
technique.  Careful controls are needed to ensure that Cys mutation per se is not 
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perturbing to structure or function.  Some groups have developed alternative ligation 
chemistries to avoid Cys or refined desulfurization reactions to convert Cys to Ala.(163, 
164) Another concern is that truncation of a protein for expressed protein ligation can 
disrupt protein stability and this can lead to low yields or even the need for refolding. The 
gyrase intein can function in the presence of moderate concentrations of denaturant, 
partly alleviating this problem, but recovering functional protein after removing 
denaturing agents is often challenging. Despite these limitations, expressed protein 
ligation is a relatively attractive method for the study of protein posttranslational 






Chapter 2: Molecular Features of PTEN Regulation by C-terminal Phosphorylation 
 
2.1  Introduction 
PTEN is a phosphatidyl 3,4,5-triphosphate (PIP3) lipid phosphatase that is 
frequently inactivated in cancer by mutation, epigenetic silencing, or post-translational 
modifications (PTMs) (7, 8, 20, 165-169).  Loss of PTEN function allows unabated 
production of PIP3 from PIP2 by PI3-kinases and stimulates the AKT protein kinase 
signaling pathway and cancer cell proliferation (8, 170, 171).  Understanding the 
mechanisms of PTEN regulation is therefore critical to the development of therapeutics 
that can treat a wide variety of cancers. 
  PTEN is a ~45 kDa protein composed of an N-terminal PTP-type phosphatase 
domain, a mid-section phospholipid membrane interacting C2 domain and a 50 residue 
regulatory tail(8).   A crystal structure of the core PTEN catalytic-C2 region has revealed 
intimate interactions between the catalytic and C2 domains but omitted the C-terminal 
tail, which is considered to be flexible and largely unstructured(16).  One of the most 
intensively studied set of PTMs in PTEN is a cluster of four C-terminal phosphorylations 
at Ser380, Thr382, Thr383, and Ser385(19, 23, 172, 173).  These phosphorylation 
events have been suggested to be catalyzed by protein kinases CK2 and/or GSK3β and 
demonstrated to drive a conformational change that inhibits membrane interactions and 
reduces catalytic activity(19, 23, 172, 173). 
 Several reports that shed light on the molecular basis for this phospho-
dependent regulatory event suggest that the PTEN tail-phosphorylation induces 
conformational closure involving intramolecular interactions between the tail and the 
CBR3 loop of PTEN's C2 domain(19, 173, 174). However, important aspects of this 
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structural model remain undetermined.  It is not known whether all four tail 
phosphorylation events are necessary for PTEN’s conformational closure or whether 
specific individual sites are critical for this tertiary structural change.  Recently, a mutant 
form of PTEN, ePTEN, was identified through a genetic screen as a form of PTEN that 
constitutively binds the membrane, despite C-terminal phosphorylation(175). The five 
mutations in ePTEN, Q17R, R41G, E73D, N262Y, and N329H, are widely spaced 
throughout the PTEN domains(175).  It was hypothesized, but not investigated in detail, 
that these mutations disrupt the phosphorylation-driven conformational change in 
PTEN(175).  Other studies on PTEN including H/D exchange experiments have 
suggested that the catalytic domain and/or the N-terminus may also interact with the 
phosphorylated tail(176). 
 To help clarify these phospho-PTEN structural issues, we have applied 
expressed protein ligation(158)  to generate several semisynthetic phosphorylated forms 
of PTEN, and we assessed their activity and tail interactions.  We demonstrated that 
there is an approximately proportional relationship between the number of phosphates 
and degree of conformational closure.  In contrast to expectations, tetraphosphorylated 
ePTEN (4p-ePTEN) showed a closed conformation similar to that of wt 4p-PTEN.  
However, mutations of a cluster of Lys and Arg residues in the Cα2 loop relaxed 
phospho-tail interactions with the PTEN body.  The incorporation of a 
benzolyphenylalanine in the C-tail was employed in photocrosslinking experiments and 
provided direct evidence for a tail-catalytic domain interaction.  Here, we describe how 
this biochemical analysis of a new set of semisynthetic PTENs has led to significant 




2.2  Methods 
 
2.2.1  Reagents: 
Soluble diC6-PIP3 was purchased from Avanti Polar Lipids (Alabaster, AL).  Anti-
phospho-PTEN antibody was from abcam (ab131107), and anti-total PTEN antibody 
was from Santa Cruz (sc-7974).  Calf intestinal alkaline phosphatase (CIP) was 
purchased from New England Biolabs (M0290).  MESNA was supplied from Sigma (St. 
Louis, MO). All canonical Fmoc-amino acids were from EMD (Billerica, MA), whereas 
Fmoc-L-p-benzoylphenylalanine and Fmoc-L-Lys(biotin)-Wang resin were purchased 
from Novabiochem and Iris Biotech, respectively.  All other reagents were of the highest 
quality and were purchased from either Sigma or Fisher. 
 
2.2.2  Peptide synthesis: 
Peptides were synthesized using the PS3 peptide synthesizer or the Prelude X 
peptide synthesizer from Protein Technologies (Tuscon, AZ) using conventional Fmoc 
solid phase peptide synthesis strategies. Synthetic peptides were estimated to be 
greater than 90% pure after HPLC and their correct structures were confirmed by matrix-
assisted laser desorption ionization (MALDI) mass spectrometry.  Peptide samples were 
spotted using the sandwich method with α-cyano-4-hydroxycinnamic acid as the matrix 
(10 mg/mL CHCA in 50% acetonitrile, 5 mM ammonium citrate).  Mass spectra were 
acquired using the Voyager-DE STR BioSpectrometry Workstation (Applied Biosystems) 
by averaging 100 shots using a linear detector in either positive (unphosphorylated 
peptides) or negative ion (phosphorylated peptides) mode. 
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2.2.3  Generation and purification of semisynthetic PTEN: 
 Expressed protein ligation was used to generate different semisynthetic 
phosphorylated PTENs as previously reported by Bolduc et al(19).  In brief, a C-terminal 
truncated PTEN (tPTEN: aa1-378) fused to Mycobacterium xenopi GyrA intein and 
chitin-binding domain (tPTEN-intein-CBD) was subcloned into the pFastBac-1 vector 
and transformed into DH10Bac competent cells, in order to produce a bacmid containing 
the appropriate PTEN sequence.  Site-directed mutants were generated by standard 
quikchange methods using the primers shown in Table 1.  The bacmid containing t-
PTEN-intein-CBD was then transfected into Sf-21 insect cells to generate the 
corresponding baculovirus needed for protein expression.  High Five insect cells were 
infected with the baculovirus at a cell density of 1 million/mL and cultured for 48 h at 
27°C to express tPTEN-intein-CBD.  The final culture was then harvested by 
centrifugation and the cell pellet lysed with a Dounce homogenizer by 40 strokes in 40 
mL of 50 mM HEPES pH 7.5, 250 mM NaCl, 1 mM EDTA, 10% glycerol, and one tablet 
of complete EDTA-free protease inhibitor cocktail (Roche Diagnostics).  The soluble 
lysate was then incubated with fibrous cellulose (Sigma) for 30 min at 4°C to remove 
chitinase. Next, t-PTEN-intein-CBD was immobilized by passing it over chitin resin, 
followed by rigorous washing with 25 mM HEPES pH 7.5, 250 mM NaCl, 1 mM EDTA, 
0.1% Triton and 50 mM HEPES pH 7.5, 250 mM NaCl, 1 mM EDTA.  Semisynthetic 
PTEN was then generated by incubating the t-PTEN-intein-CBD-bound chitin resin for 
48 – 72 h at room temperature with 50 mM HEPES pH 7.2, 250 mM NaCl, 400 mM 
MESNA, and 2 mM of the corresponding C-terminal tail peptide.  Truncated PTENs were 
generated by incubating the chitin resin with 50 mM HEPES pH 7.2, 250 mM NaCl, 400 
mM MESNA, and 40 mM cysteine for 24 h at room temperature.  Following the ligation 
reaction, semisynthetic PTEN was eluted from the chitin resin in 50 mM Tris pH 8.0, 5 
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mM NaCl, 5 mM DTT, followed by dialysis with the same buffer to remove unreacted 
peptide and salt from the ligation reaction.  The semisynthetic PTEN was then further 
purified by FPLC-anion exchange chromatography (MonoQ, GE Healthcare) using a 240 
mL linear gradient (0% to 50% Buffer B), whereby Buffer A is the dialysis buffer and 
Buffer B is 50 mM Tris pH 8.0, 1 M NaCl, 5 mM DTT.  
 
2.2.4  Enzyme activity assay:   
Lipid phosphatase activity of PTEN towards the aqueous soluble substrate diC6-
PIP3 was measured by monitoring phosphate release using the Malachite Green assay 
kit (R&D Biosystems) at 620 nm.  Initial velocities were measured for a 25 μL reaction 
containing 50 mM Tris pH 8.0, 10 mM BME, 0.05 mg/mL ovalbumin, and varying 
concentrations of diC6-PIP3 (20–160 μM).  Reactions were initiated with 0.5–20 μg of 
the corresponding PTEN and reaction rates were measured for 5–10 minutes at 30°C.  
Reactions were then quenched and inorganic phosphate measured using the Malachite 
Green assay kit.  Background corrections were performed with quenched enzyme.  All 
measurements were performed in duplicate on at least two separate occasions and 
replicates typically agreed within 20%.  The kcat/Km measurements derived from this data 
were obtained using the Michaelis-Menten equation or a linear plot when no evidence of 
saturation was apparent by visual inspection.  
 
2.2.5  Western blotting and alkaline phosphatase sensitivity assay: 
Semisynthetic phospho-PTEN forms were subjected to alkaline phosphatase 
treatment over a period of up to 300 min in 50 mM Tris pH 8.0, 10 mM BME, 1 μM of the 
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corresponding phospho-PTEN, and 1 μM calf intestinal alkaline phosphatase (NEB).  
Reaction samples were quenched in SDS-loading dye at 95°C and the fraction of 
phospho-PTEN remaining was measured by Western blot analysis using an antibody to 
the PTEN phospho-C-tail cluster (abcam) in combination with a HRP-conjugated anti-
rabbit secondary antibody.  Western positive bands were detected using Amersham ECL 
Western blotting detection reagent with Syngene’s PXi and quantified by ImageJ image 
quantification software. Phospho-tail half-liives were calculated using a single 
exponential decay curve. All measurements were performed at least twice on separate 
occasions and half-lives from replicates typically agreed within 30%.   
 
2.2.6  UV-induced C-terminal tail crosslinking: 
An 18-mer tetraphosphorylated C-terminal tail peptide was synthesized with a 
photoactivatable p-benzoylphenylalanine (Bpa) in the place of Phe392 and an artificial 
C-terminal lysine that was Nε-biotinylated using conventional Fmoc peptide synthesis 
strategies and ligated to immobilized t-PTEN-intein-CBD using the methods described 
above.  UV-induced crosslinking was performed with 50 μg of PTEN diluted with 50 mM 
Tris pH 8.0, 10 mM DTT to ~150 μg/mL.  In a quartz reaction chamber with circulating 
water at 4°C and constant stirring, 4p-PTEN containing Bpa was UV-irradiated at 365 
nm with a Blak-Ray C50 UV lamp for 3 h.  Next, the UV-irradiated 4p-PTEN was treated 
with bovine alkaline phosphatase (Sigma) at a final concentration of 1 μM for 2 h at room 
temperature.  The alkaline phosphatase-treated cross-linked PTEN samples were 
subjected to buffer exchange with 50 mM NH4HCO3 followed by reduction with 5 mM 
tris(2-carboxyethyl)phosphine (TCEP) for 30 min at 60 °C and alkylation with 10 mM 2-
chloroacetamide for 30 min at room temperature in the dark. The samples were de-
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salted using Protein Desalting Spin Columns and overnight digestion was conducted 
using trypsin (2% wt/wt) for 16 h at 37 °C. The digests were acidified by the addition of 
trifluoroacetic acid to 0.1 % final concentration prior to desalting using C18 solid phase 
extraction. The eluate was dried in a SpeedVac and re-constituted in avidin column 
loading buffer for enrichment of the biotinylated peptides. Peptides were eluted from the 
avidin column with 2 mM biotin buffer (100 mM Na2PO4 pH 7.0, 150 mM NaCl, 2 mM 
biotin). The peptide concentration was approximated by UV absorption using a 
NanoDrop (A280nm) and the samples were re-constituted in a sufficient volume of 0.2% 
formic acid in water to yield a concentration of 200 fmol/µL prior to LC-MS/MS analysis. 
 
2.2.7  Liquid chromatography-tandem mass spectrometry (LC-MS/MS): 
Chromatographic separation was performed using a Dionex Ultimate 3000 
RSLCnano system (Thermo Scientific) with a 75 µm x 15 cm Acclaim PepMap100 
separating column (Thermo Scientific) protected by a 2 cm guard column (Thermo 
Scientific). The mobile phase flow rate was 300 nL/min and consisted of 0.1% formic 
acid in water (A) and 0.1% formic acid, 95% acetonitrile (B). MS analysis was performed 
using an LTQ Orbitrap Velos Pro mass spectrometer (Thermo Scientific). The spray 
voltage was set at 2.2 kV. Orbitrap spectra were collected from 400-1800 m/z at a 
resolution of 30,000 followed by data-dependent HCD MS/MS (at a resolution of 7500, 
collision energy 35%, activation time 0.1 ms) of the 10 most abundant ions using an 
isolation width of 2.0 Da. Charge state screening was enabled to reject the generation of 
MS/MS spectra for unassigned and singly charged precursor ions. A dynamic exclusion 




2.2.8  Data analysis:   
Mass spectrometry data from the cross-linked PTEN samples were analyzed 
using Crossfinder version 1.0 (20,21) with the default parameters. Prior to analysis with 
Crossfinder, MS/MS data were converted to mzXML files using ProteoWizard. 
 
2.2.9 Crystallography: 
A crystallographic form of PTEN (Crystal PTEN) was generated by deleting the 
N-terminal 7 residues, the C-terminal 51 residues, and the D2 loop within the C2 domain 
(residues 286-309). Crystal PTEN (200 µM) is mixed with 2 mM 4p-17mer peptide 
(YpSDpTpTDpSDPENEPFDED), and then screened by hanging drop in 96-well plates 
for crystallization conditions. PTEN crystals are obtained in 1.6 M sodium/potassium 
phosphate, pH 6.5, and optimized by varying the salt concentration and pH. The 
diffraction data was collected at ALS beam line 502 on a DECTRIS Pilatus 6M detector 
(wavelength 1.0 Å and temperature 100 K). All diffraction data were processed, 
integrated and scaled with HKL-2000.  
 The PTEN structure was determined by molecular replacement using the 
program AMoRe and the published structure of PTEN (PDB ID 1D5R)(177) as the initial 
search model. The model was re-built manually with iterative rounds of Coot and refined 
using Refmac5 from the CCP4 suite. The final structure was refined to 3.1 Å. All figures 
were rendered with PyMOL. 
 
2.3  Results 
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2.3.1  Individual tail phosphorylation effects on PTEN conformation: 
To assess the specific effects of the individual Ser/Thr phosphorylations among 
Ser380, Thr382, Thr383, and Ser385, we employed expressed protein ligation to 
generate individual semisynthetic phospho-forms of PTEN.  In this way, aa1-378 was 
produced as an intein fusion protein using a baculovirus expression system and then 
reacted with MESNA to generate the PTEN recombinant fragment C-terminal thioester 
(Figures 6A and 6B).  In addition, we synthesized a series of eight new 25mer N-Cys 
containing mono-, di-, and tri-phosphorylated C-terminal peptides, along with the 
unphosphorylated and tetra-phosphorylated peptides prepared previously.  These 
peptides were then chemoselectively ligated individually to the recombinant PTEN 
thioester with high efficiency (>80%) and then the semisynthetic full-length PTEN 
proteins purified using anion exchange chromatography to >90% purity (Figure 6C).  As 
shown previously (14), the introduction of Cys379 (in place of Tyr379) and the conditions 
of ligation are well-tolerated by PTEN regarding its catalytic activity. 
 We then measured the PIP3 phosphatase activity of these semisynthetic 
phospho-PTENs using soluble diC6-PIP3 substrate and monitoring inorganic phosphate 
release using malachite green.  As shown in Figure 7 and Table 1, the 
monophosphorylated forms, p380-PTEN, p382-PTEN, p383-PTEN, and p385-PTEN all 
showed a modest reduction in catalytic efficiency, with each showing a kcat/Km 
approximately 3-fold below that of unphosphorylated PTEN (wt n-PTEN).   The three di-
phosphorylated PTENs 2p-380/382-PTEN, 2p-382/383-PTEN, and 2p-380/385-PTEN 
each hydrolyze diC6-PIP3 approximately 6-fold below that of wt n-PTEN.  The 
triphosphorylated PTEN form 3p-380/382/383-PTEN showed approximately a 12-fold 
reduction in catalytic efficiency compared with wt n-PTEN, and its catalytic efficiency 





Figure 6: Generation of unmodified, mono-, di-, tri-, and tetra-phosphorylated semisynthetic PTEN proteins.  
(A) PTEN is composed of a protein tyrosine phosphatase (PTPase) domain, a C2 domain and a regulatory 
C-terminal tail. The cluster of phosphorylation (S380/T382/T383/S385) is highlighted. (B) C-terminal 
truncated PTEN (t-PTEN, 1-378) with a thioester at the C-terminus is generated from intein fusion and then 
treated with mercaptoethanesulfonate (MESNA), and is then ligated to the synthetic peptide containing 
different combinations of pSer and pThr (mono: p380, p382, p383, p385; di: 2p-380/382, 2p-380/385, 2p-
382/383; tri: 3p-380/382/383; tetra 4p-380/382/383/385). X=Ser/Thr/pSer/pThr. (C) Coomassie stained 10% 
SDS-PAGE gel of the set of differentially phosphorylated semisynthetic PTEN proteins. Ligation of t-PTEN-
thioester and the specific peptide proceeds at a constant rate for 48 hours, and the full-length PTEN is 
further purified by FPLC-anion exchange chromatography using MonoQ column. The final protein is >90% 
pure. 1. n-PTEN, 2. p380-PTEN, 3. p382-PTEN, 4. p383-PTEN, 5. p385-PTEN, 6. 2p-380/382-PTEN, 7. 2p-
382/383-PTEN, 8. 2p-380/385-PTEN, 9. 3p-380/382/383-PTEN, 10. 4p-PTEN.  
  






Figure 7: Catalytic activity of the set of differentially phosphorylated semisynthetic PTENs toward a range of 
diC6-PIP3 substrate concentrations. (A) n-PTEN and mono-phosphorylated PTEN kinetics, (B) di-















Phospho-tail half-life after alk. phos. 
treatment 
t1/2 (min) 
wt n-PTEN 22 ± 5 ND2 
p380-PTEN 6 ± 1 3 ± 2 
p382-PTEN 7 ± 1 ND2 
p383-PTEN 6 ± 4 ND2 
p385-PTEN 9 ± 3 ND2 
2p-380/382-PTEN 3.1 ± 0.1 6 ± 1 
2p-382/383-PTEN 3.4 ± 0.2 ND2 
2p-380/385-PTEN 2.9 ± 0.2 20 ± 5 
3p-380/382/383-PTEN 1.8 ± 0.1 96 ± 13 
wt 4p-PTEN 1.7 ± 0.1 104 ± 17 
wt t-PTEN 18 ± 5 ND2 
Cα2D-tPTEN 12 ± 3 ND2 
Cα2D-4p-PTEN 3.3 ± 0.1 16 ± 5 
Cα2A-tPTEN 15 ± 2 ND2 
Cα2A-4p-PTEN 3.1 ± 0.2 15 ± 2 
n-ePTEN 49 ± 23 ND2 
4p-ePTEN 8 ± 1 141 ± 26 
3R/D-4p-PTEN ND 69 ± 13 
1 Error reported as ± standard error 





no single phospho-modification of the Ser/Thr C-terminal cluster is dominant and that 
each is partially additive in antagonizing catalysis. 
 To assess the effects of the particular phosphorylation events on PTEN 
conformation, the mono-, di-, and tri-phosphorylated semisynthetic PTENs were treated 
with alkaline phosphatase to gauge tail accessibility. As reported previously, natively 
folded 4p-PTEN versus denatured 4p-PTEN shows resistance to tail phosphate removal 
catalyzed by the non-specific hydrolase alkaline phosphatase(19). Natively folded 4p-
PTEN's resistance to alkaline phosphatase is understood to be caused by the masking 
of the phospho-tail through its intramolecular interactions with the PTEN body.  We first 
determined which of the mono-, di-, and tri-phosphorylated semisynthetic PTENs are 
recognized by a commercially available phospho-PTEN Ab used in Western blotting.  
We found that all forms of p380-containing semisynthetic PTEN gave a strong Western 
blot signal with the anti-phospho-PTEN Ab, but those PTEN forms lacking p380 were not 
reliably detected (Figure 8A).  Thus, we proceeded to analyze the kinetics of alkaline 
phosphatase-catalyzed dephosphosphorylation of p380-PTEN, 2p-380/382-PTEN, 2p-
380/385-PTEN, and 3p-380/382/385-PTEN benchmarked to wt 4p-PTEN standard 
(Figures 8B and 8C and Table 1).  These measurements showed that p380-PTEN was 
the most rapidly dephosphorylated by alkaline phosphatase (t1/2 = 3 min), 30-fold faster 
than wt 4p-PTEN (t1/2 = 104 min), and was followed closely by 2p-380/382-PTEN (t1/2 = 6 
min), which was ~20-fold faster than wt 4p-PTEN.  2p-380/385-PTEN (t1/2 = 20 min) was 
dephosphorylated by alkaline phosphatase  ~5-fold faster than wt 4p-PTEN.  The 
sensitivity of 3p-380/382/385-PTEN (t1/2 = 96 min) to alkaline phosphatase was nearly 
identical to that of wt 4p-PTEN.  Taken together, the pattern of alkaline phosphatase 





Figure 8: Alkaline phosphatase sensitivity of the set of differentially phosphorylated semisynthetic PTENs.  
(A) Western blot of the set of differentially phosphorylated semisynthetic PTENs using an anti-phospho-
PTEN (S380/T382/T383) antibody. 1. n-PTEN, 2. p380-PTEN, 3. p382-PTEN, 4. p383-PTEN, 5. p385-
PTEN, 6. 2p-380/382-PTEN, 7. 2p-382/383-PTEN, 8. 2p380/385-PTEN, 9. 3p-380/382/383-PTEN, 10. 4p-
PTEN. (B) Time course of the rate of dephosphorylation of the p380-containing semisynthetic PTENs after 
alkaline phosphatase treatment analyzed by Western blot. (C) Quantification of the time courses of the 
Western blot data in Fig. 3B (n=2). Error bars reported as ± standard error. 
  
 





indicating that the individual phosphorylation events show partial additivity in driving the 
tail interaction with the PTEN body. 
 
2.3.2  Analysis of mutant semisynthetic 4p-PTENs:  
We next combined site-directed mutagenesis along with expressed protein 
ligation to prepare three semisynthetic 4p-PTEN proteins to investigate the biochemical 
properties of the ePTEN mutant residues and those of the PTEN Cα2 loop.  As 
previously mentioned, cellular expression of ePTEN indicates that it localizes to the 
plasma membrane, suggesting that tail phosphorylation may be unable to drive a closed 
PTEN conformation(175).  PTEN's Cα2 loop has been implicated in membrane binding 
and in H/D exchange experiments to participate in PTEN's phospho-tail mediated 
conformational change(16, 176).  The 4p-ePTEN mutant containing Q17R, R41G, E73D, 
N262Y, and N329H was prepared by semisynthesis as described above, as were two 
4p-PTEN Cα2 mutants, Cα2D (K327D, K330D, K332D and R335D) and Cα2A (K327A, 
K330A, K332A, and R335A) to >90% purity (Figure 9).  Interestingly both n-ePTEN and 
4p-ePTEN had 2-and 5-fold higher diC6-PIP3 phosphatase catalytic efficiencies 
compared with their wt counterparts (Figure 9 and Table 1). However, the diC6-PIP3 
phosphatase catalytic efficiency of 4p-ePTEN was a marked 6-fold lower than that of n-
ePTEN (Figure 9B and Table 1) suggesting that tail phosphorylation could drive ePTEN 
into a closed state.  Furthermore, 4p-ePTEN alkaline phosphatase sensitivity showed a 
slightly (~40%) longer half-life of phospho-tail hydrolysis relative to that of wt 4p-PTEN 
(Figures 10A and 10B and Table 1).  These results suggest that the point mutants of 
ePTEN do not substantially weaken phospho-tail-PTEN body interactions, and there is 








Figure 9: SDSPAGE analysis and catalytic activity of a series of mutant semisynthetic PTENs toward a 
range of diC6-PIP3 substrate concentrations.  (A) Coomassie stained 10% SDS-PAGE gel of semisynthetic 
PTEN mutants.   1. 2. BB-4p-PTEN, 3. Cα2A-4p-PTEN, 4. Cα2A-t-PTEN, 5. Cα2D-4p-PTEN, 6. Cα2D-t-
PTEN, 7. 4p-ePTEN, 8. 3R/D-4p-PTEN, 9. 3R/D-t-PTEN.  (B) Catalytic activity of ePTEN forms with diC6-
PIP3 (n=2); Q17R, R41G, E73D, N262Y, N329H.  (C) Catalytic activity of Cα2 loop mutant PTEN forms with 
diC6-PIP3; Cα2D = K327D, K330D, K332D, R335D; Cα2A = K327A, K330A, K332A, R335A (n=2). 
 
  




 In contrast, analysis of the 4p-PTEN Cα2 mutants demonstrated that this region 
participates significantly in phosphorylation-mediated conformational change.  Both the 
Cα2D and Cα2A 4p-PTEN mutants showed increased catalytic efficiencies of diC6-PIP3 
hydrolysis relative to that of 4p-PTEN (Figure 9C and Table 1).  While still lower than the 
truncated PTEN Cα2 mutants that lack phospho-tails, the lipid phosphatase activities of 
these 4p-PTEN Cα2 mutants suggest that replacement of these Lys and Arg residues 
weakened phospho-tail interactions in phosphorylated PTEN.  Furthermore, both Cα2D 
and Cα2A 4p-PTEN exhibited a marked 6-fold greater sensitivity to alkaline 
phosphatase-mediated tail dephosphorylation compared with wt 4p-PTEN.  The fact that 
both the Asp and Ala replacements of the Lys/Arg residues in the Cα2 4p-PTEN mutants 
display similar behaviors is consistent with the possibility that one or more of the Lys/Arg 
side chains are making important electrostatic interactions with residues in the anionic 
PTEN tail. 
 
2.3.3  Photo-crosslinking of benzoylphenylalanine containing-4p-PTEN:   
To further investigate the structural basis of phospho-tail-body interactions within 
4p-PTEN, we pursued a photo-crosslinking strategy.  In this regard, Phe392 was 
replaced with the photo-activatable benzoylphenylalanine (Bpa) and a C-terminal biotin-
modified Lys.  In this semisynthetic strategy, a 18mer N-Cys peptide (Figure 11A) was 
used rather than the full-length 25mer tail for synthetic ease and because prior studies 
have shown the 4p-17mer tail is sufficient to promote high affinity interaction with the 
core of PTEN(19).  This Bpa/biotin-modified semisynthetic 4p-PTEN (BB-4p-PTEN) was 
efficiently produced and appeared greater than 90% pure after anion exchange 









Figure 10:  Alkaline phosphatase sensitivity of different semisynthetic phospho-PTEN mutants.  (A) Western 
blot of time course from the alkaline phosphatase treated 4p-ePTEN (Q17R, R41G, E73D, N262Y, N329H) 
and wt 4p-PTEN.  (B) Quantification of the alkaline phosphatase assay for 4p-ePTEN and wt 4pPTEN (n=3).  
(C) Western blot of time course from the alkaline phosphatase treated Cα2D-4p-PTEN (K327D, K330D, 
K332D, R335D), Cα2A-4p-PTEN (K327A, K330A, K332A, R335A), and wt 4p-PTEN.  (D) Quantification of 








phosphatase treatment (to remove the mass spectrometry electrospray ionization 
suppressive effects of the phosphates) and trypsinization and avidin treatment to enrich 
for biotin-containing peptides.  These peptides were then subjected to LC-MS/MS and 
then the data were analyzed using Crossfinder(178, 179).  This led to the identification of 
a crosslinked peptide that contained a C-terminal peptide (379-
CSDTTDSDPENEP(B)DEDKbio-396) attached to an N-terminal peptide (42-
LEGVYRNNIDDVVR-55) (Figures 11B and 11C).  The assignment of this crosslinked 
peptide was based on a combination of its intact molecular mass (4090.7 Da) as well as 
its fragmentation pattern using tandem mass spectrometry, although the site of 
conjugation to the N-terminal peptide (between Gly45 and Ile50) could not be precisely 
defined (Figure 11C).  This crosslinked peptide was not detected in the absence of UV 
irradiation.  These data thus suggest that the C-tail can access a conformation that 
places the C-terminal peptide in proximity to the N-terminal catalytic domain segment 
aa42-55. 
 To further probe the importance of this interaction, we generated semisynthetic 
4p-PTEN containing three point mutations in the vicinity of the three-dimensional surface 
of the crosslinked N-terminal segment, R41D, R47D, and R74D (3R/D).  Even unligated 
3R/D-PTEN mutant showed significantly impaired catalytic activity  (Figure 12A), as 
expected from prior studies that have investigated the phosphatase effects of mutating 
Arg47(180, 181).  Thus, it was not feasible to use diC6-PIP3 hydrolytic activity to gain 
insight into the phosphorylation effects of 3R/D-4p-PTEN.  To assess the conformation 
of the 3R/D-4p-PTEN, we relied on alkaline phosphatase sensitivity.  In these 
experiments, we found that 3R/D-4p-PTEN (t1/2 = 63 min) showed approximately a 2-fold 
rate increase in alkaline phosphatase-mediated dephosphorylation compared with 4p-






Figure 11: BB-4p-PTEN, photocrosslinking and mass spectrometry analysis.  (A) MALDI-TOF MS spectrum 
of 18mer synthetic peptide containing tetraphosphorylation (Ser380, Thr382, Thr383, Ser385), Bpa at 
position 392, and a C-terminal biotinylated lysine used for expressed protein ligation. (B) Isotopic distribution 
of a 4+ charged crosslinked peptide with the reported mass, m/z, and Δm from Crossfinder.  (C) High 
resolution tandem-MS spectrum of the crosslinked peptide. (D) PTEN crystal structure (PDB: 1D5R) 












Figure 12: Conformational analysis of the 3R/D PTEN mutant.  (A) Catalytic activity of wt t-PTEN (123 ± 4 
nmoles/min/mg) compared to 3R/D t-PTEN (<4 nmoles/min/mg) with 160 μM diC6-PIP3 (n=2).  (B) Western 
blot of time course of dephosphorylation of alkaline phosphatase-treated 3R/D-4p-PTEN (R41D, R47D, 
R74D) and wt 4p-PTEN.  (C) Quantification of the alkaline phosphatase assay for 3R/D-4p-PTEN and wt 










contribution of the N-terminal catalytic segment in stabilizing the closed conformation of 
4p-PTEN. 
 
2.3.4  Co-crystallization of PTEN with phosphorylated C-tail peptide   
To obtain detailed information about how the phosphorylated C-tail inhibits 
PTEN, we tried to get a high-resolution structure of the phosphorylated form of PTEN. 
The tetra-phosphorylated PTEN C-tail peptide showed the strongest inhibition of the 
phosphatase activity of PTEN using soluble PIP3 substrate, indicating a high affinity 
binding of the phospho-peptide to the protein. Taking advantage of this high affinity 
binding, we hypothesized that it might be possible to co-crystallize the truncated version 
of PTEN that was used to solve the crystal structure of partial PTEN in complex with our 
synthetic tetra-phosphorylated C-tail peptide.  
To facilitate the crystallization, we synthesized a peptide lacking the last eight 
residues of the original C-tail peptide affording the 4p-17mer. The version of PTEN used 
in crystallization trials deletes the 7 N-terminal amino acid residues, the C-tail residues 
from 354 to 403, and a D2 loop (286-309). Since this construct was used to solve the 
crystal structure of PTEN by Pavletich and coworkers, we call it crystal-PTEN.(16) We 
confirmed that the 4p-17mer also inhibits crystal-PTEN's phosphatase activity with high 
potency, with IC50 about 1 µM (Figure 13A). The mixture of 200 µM crystal-PTEN and 2 
mM 4p-17mer peptide with 25 mM DTT are combined with the crystallization screening 
kit that contains different precipitant and buffer at various concentrations and pH, in the 
hanging drop vapor diffusion system to screen the optimal conditions.  
We got several hits, and optimized them. The first hit was obtained with 1.6 M 
sodium potassium phosphate at pH 6.5. In this one we got nice crystals and were able to 
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see X-ray diffraction. The structure was  solved using molecular replacement at the 
resolution of 3.1 Å (Figure 13B). However, in this structure, we did not observe electron 
density for the C-tail peptide, it was almost identical to the previous known structure of 
PTEN. Under this condition, the phosphorylated peptide did not bind to PTEN. From this, 
we learned that the high salt condition could interrupt the binding of phosphorylated C-
tail with PTEN which is very sensitive to ionic strength. This observation was further 
confirmed using PTEN phosphatase activity assays that adding 150 mM NaCl to the 
assay buffer sharply reduced the potency of 4p-peptide to inhibit PTEN activity (Figure 
13C). Thus, in subsequent crystal screening, we focused on low-salt conditions, which 
we hoped would be more conducive to allowing co-crystallization of PTEN with the 
phospho-peptide. We got another two hits. The first one involved 100 mM SPG, pH 8.0, 
and 25% PEG1500. Small crystals were observed. However, crystals in this condition 
could never been reproduced except using the exact solution from the screening kit. The 
other hit we got employed 20% PEG3350, 100 mM Bis-Tris Propane, pH7.5, 200 mM 
sodium potassium tartrate. This condition could be reproduced and partly optimized by 
changing the concentration of PEG3350, pH and concentration of sodium potassium 
tartrate. However, after a lot of effort, we were still unable to grow crystals of sufficient 
size and shape suitable for structural analysis.  
 
2.4  Discussion 
The application of protein semisynthesis, mutagenesis, and photocrosslinking 
has been integrated to refine our understanding of how phosphorylation of a cluster of 






Figure 13: Co-crystallization of crystal-PTEN and phosphorylated C-tail peptide. (A) Malachite Green Assay 
of crystal-PTEN with different peptides. While 10 uM non-phosphorylated 25mer peptide showed little 
inhibition, the 4p-25mer, and 4p-17mer which will be used in co-crystallization, showed very potent inhibition 
of PTEN phosphatase activity. (B) Crystal structure solved by us (purple) superimposed with the published 
structure of PTEN (green). (C) Malachite Green Assay of crystal-PTEN with different peptides in two 







work, it was unclear if any single phosphorylation site in PTEN would be predominantly 
or wholly responsible for inducing the PTEN conformational change and the influence of 
the three other sites would be negligible. Our data shown here supports the idea that 
each of the four sites can contribute incrementally to stabilizing the closed PTEN 
conformation and at least three sites are needed to match the full effects of 
tetraphosphorylated PTEN. These results imply that the surface of interaction between 
the phospho-tail and the PTEN body may be rather broad to encompass multiple contact 
sites with these phosphates.  These findings also suggest the concept that a dynamic 
step-wise degree of PTEN conformational closure may occur by modifying only a subset 
of the tail Ser/Thr residues, which in turn could give rise to a sliding scale of cellular 
signaling effects.  Our results also highlight that the antibody used here cannot readily 
distinguish between monophosphorylated p380 and the multiply modified forms that 
contain p380.  This suggests the need for caution in interpreting Western blots and 
immunocytochemistry data that rely on this reagent for signaling analysis. 
 Several models have been proposed regarding where the phospho-tail in PTEN 
contacts the core of the protein(19, 173, 174).  In the current study, we found additional 
evidence for key interactions between the PTEN C2 domain and the phospho-tail.  Prior 
studies have shown that the CBR3 loop of the PTEN C2 domain is involved in the 
phospho-tail interactions(19), with an 8-fold enhanced sensitivity to alkaline 
phosphatase-catalyzed tail dephosphorylation compared with 4p-PTEN.  However, while 
the penta-Lys (260,263,266,267, and 269) to penta-Asp CBR3 loop 4p-PTEN mutant 
appears to have a relatively open structure, mutation of the penta-Lys motif to penta-Ala 
is quite similar to wt 4p-PTEN(19).  Thus, it appears that none of the CBR3 loop Lys 
residues are making key electrostatic interactions with the phospho-tail, and only when 
replaced with the negatively charged Asp residues do they prevent conformational 
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closure, arguing for a more indirect role in stabilizing the closed conformation.  In 
contrast, as shown here the Cα2 Lys/Arg sidechains cannot be substituted functionally 
by Ala, suggesting that these basic residues are more directly involved in tail phospho-
interactions. 
  Some prior experiments including H/D exchange, mutagenesis, and protease 
sensitivity have suggested that the catalytic domain of PTEN might also somehow 
participate in phospho-tail interactions(19, 173, 176).  Through the use of photo-
crosslinking, we find that at least part of the phospho-tail binds to an N-terminal segment 
in the PTEN catalytic domain.  Mutagenesis of this segment is consistent with this region 
playing a partial role in mediating the conformational closure of phosphorylated PTEN.  If 
we consider the energetic sum of the alkaline phosphatse sensitivity parameters of   the 
N-terminal segment (2-fold), the Ca2 loop (6-fold), and the CBR3 loop (8-fold) mutants 
reported here and previously, we can more than account for the 25-fold protection 
measured when comparing folded and unfolded 4p-PTEN. Thus, it is plausible that these 
three PTEN surfaces are fully responsible for locking the phospho-tail to the PTEN 
body(19). It is perhaps noteworthy that this N-terminal segment as well as the CBR3 
loop and the Cα2 loop all have been implicated in PTEN's membrane recruitment(8, 176, 
180, 181).  It is therefore reasonable to postulate that the PTEN phosphate tail acts as a 
molecular mimic of the phospholipid membrane.  These results underscore the very 
large interaction surface that may govern the 4p-PTEN conformational closure.  
 The observation that 4p-ePTEN behaves conformationally similarly to wt 4p-
PTEN was unexpected, given the dramatic cellular phenotype associated with 
ePTEN(175). We speculate that these ePTEN point mutations may strengthen a specific 
protein-protein or protein lipid interaction between PTEN and a molecule not yet 
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identified.  Future work will be needed to address these possibilities that could uncover 
new targets to enhance cellular PTEN functions. 
 This study also illustrates the power of expressed protein ligation in elucidating 
how a complex series of post-translational modifications (PTMs) can alter the structure 
of a protein(157).  As mass spectrometry has identified hundreds of thousands of PTMs 
in proteins, it has become daunting to cope with illuminating the structural and functional 
effects of these PTMs at an individual protein level.   The incorporation of four 
phosphorylations, a benzoylphenylalanine, and a biotin tag site-specifically into a single 
folded protein of this size would have been difficult to achieve without expressed protein 
ligation.  Expressed protein ligation when coupled with other biochemical, biophysical, 
and analytical approaches thus offers atomic precision in working through the 21st 







Chapter 3: Enzymatic Analysis of PTEN Ubiquitination by WWP2 and NEDD4-1 E3 
Ligases 
 
3.1  Introduction 
As described in Chapter 2, PTEN loss of function mutations occur commonly in a 
wide array of human cancers, allowing for the increase in PIP3 levels fueled by PI3-
kinases that in turn allosterically activate Akt protein kinase and drive neoplastic 
growth.(170, 182-185)  Beyond mutation, PTEN's activity is regulated by other 
mechanisms including post-translational modification.(20, 23, 168, 172, 174)  Two types 
of post-translational modifications occurring on PTEN are phosphorylation and 
ubiquitination.(29, 168)  Our study along with others have suggested that a cluster of 
phosphorylations at residues Ser 380, Thr 382, Thr 383 and Ser 385 can drive an 
intramolecular interaction with the PTEN C2 domain, resulting in reduced membrane 
association and catalytic activity.(19)  Somewhat paradoxically, this phospho-cluster has 
also been reported to enhance the cellular stability of PTEN.(20)  However, the evidence 
of this phosphorylation effect on PTEN stability has been indirect, relying on 
mutagenesis of the 380-385 cluster to Ala.  Moreover, it is unknown if this PTEN 
instability is related to changes in its cellular localization, altered cellular signaling, or 
differential ubiquitination. 
 Three PTEN ubiquityltransferase E3 ligases that have been reported are 
NEDD4-1, WWP2, and XIAP.(27, 28, 30)  NEDD4-1 and WWP2 E3 ligases belong to the 
subset of ubiquityltransferases that have a catalytic HECT domain that operates with E1 
and E2 ligases to catalyze ubiquityl transfer to Lys residues on target proteins.(60, 85)  
Unlike the more common RING domain E3 ligases, the HECT domain gets charged by 
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ubiquitin on a nucleophilic Cys residue to form an intermediate E3-ubiquitin thioester.(70, 
85)  This E3 catalytic intermediate is in turn attacked by substrate Lys residues affording 
ubiquitylated proteins.(70) XIAP is a member of the larger family of RING domain E3 
ligases that are Zn-binding proteins and serve as a template facilitating transfer of 
ubiquitin from the E2 enzyme Cys thioester intermediate to a Lys on a target 
substrate.(186, 187) 
 In this study, we analyze with purified proteins the NEDD4-1, WWP2, and XIAP 
catalyzed ubiquitination of PTEN in its unphosphorylated and phosphorylated states.  
We employed expressed protein ligation(158) to generate semisynthetic forms of PTEN 
that were either tetraphosphorylated on the 380-385 Ser/Thr cluster (4p-PTEN) or 
unphosphorylated on these residues (n-PTEN).  In our hands, XIAP did not catalyze 
PTEN ubiquitination, whereas both NEDD4-1 and WWP2 showed PTEN 
ubiquityltransferase activity. Compared with NEDD4-1, we found that WWP2 appears to 
more rapidly ubiquitylate n-PTEN.  NEDD4-1 showed similar ubiquitination kinetics 
toward both n-PTEN and 4p-PTEN.  In contrast, WWP2 showed a marked reduction in 
its ability to ubiquitylate 4p-PTEN versus n-PTEN.  Mass spectrometric analysis 
suggests that the two E3 ligases possess overlapping but distinct ubiquitination 
preferences for PTEN Lys specificity.  Below we describe these findings and discuss 
their relevance to PTEN regulation. 
 
3.2  Methods 
3.2.1  Reagents: 
The pGEX6p-2 WWP2 plasmid for bacterial expression of GST-WWP2 was a gift 
from Dr. Wenyi Wei at Beth-Israel Deaconess Medical Center. The pFastBac1-His-
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NEDD4-1 was described previously.(30) Human recombinant XIAP protein was 
purchased from Sigma Aldrich. Purified wild-type ubiquitin, human ubiquitin-activating 
enzyme UBE1, and human ubiquitin-conjugating enzyme UbcH5c were prepared as 
described previously.(188) The lysine-free ubiquitin (K0-Ub) and human ubiquitin-
conjugating enzyme UbcH7 were purchased from LifeSensors (PA, USA). The Colloidal 
Blue Staining Kit was purchased from Invitrogen. Anti-PTEN antibody was from Santa 
Cruz (CA, USA). Apyrase was from New England Biolabs. All other reagents were 
commercially purchased with the highest quality from either Sigma or Fisher. 
 
3.2.2  Peptide synthesis: 
Peptides were synthesized using a PS3 peptide synthesizer from Protein Technologies 
(Tuscon, AZ) using conventional FMOC peptide synthesis strategies.  They were purified 
by reversed phase HPLC on a C-18 column and the correct structures confirmed by 
MALDI mass spectrometry. 
 
3.2.3  Expression and Purification of GST-WWP2: 
BL-21 Codon Plus cells were transformed with the pGEX6p-2 WWP2 plasmid, 
and cultured in LB medium at 37 °C to reach the optimal density (OD600=0.6) in a shaker 
incubator grown on a 1 L scale. GST-WWP2 expression was induced by 0.5 mM IPTG 
at 16 °C for 20 hours. The cells were resuspended in lysis buffer (25 mM Tris-HCl pH 
8.0, 250 mM NaCl, 1 mM PMSF and 1x Roche cocktail protease inhibitors) and were 
lysed using French Press, and the lysate was loaded on glutathione agarose followed by 
washing with wash buffer (25 mM Tris-HCl pH 8.0, 250 mM NaCl, 0.1% Triton X-100). 
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The desired GST-WWP2 was eluted using 25 mM Tris-HCl pH 8.0, 250 mM NaCl 
containing 50 mM reduced glutathione at pH 8.0. Fractions containing GST-WWP2 were 
combined and dialyzed against a buffer consisting of 25 mM Tris-HCl pH 7.5, 250 mM 
NaCl, 1 mM EDTA, 5 mM DTT, and 10% glycerol and the protein was concentrated to 2 
to 5 mg/mL and flash frozen.  The yield of GST-WWP2 was 0.5 mg/L culture.  GST-
WWP2 was stored in aliquots at -80˚C after flash freezing.  
 
 3.2.4  Expression and Purification of His6-NEDD4-1: 
For NEDD4-1, the pFascBac1-His-NEDD4-1 was used to generate Bacmid to 
infect Sf21 insect cells which produced the baculovirus for NEDD4-1 expression. The 
Sf9 insect cells were infected with baculovirus and cultured at 27 °C for 48 hours. The 
cells were then harvested and resuspended in lysis buffer (25 mM HEPES pH 7.5, 250 
mM NaCl, 1 mM EDTA, 10% glycerol, 1 mM PMSF, 1x Roche cocktail protease 
inhibitors). The cells were lysed using a 40 mL homogenizer. The cell lysate from 1 L 
culture was incubated with 2.5 ml Ni-NTA resin for His-NEDD4-1 binding. After washing 
with 200 mL wash buffer (25 mM HEPES pH7.5, 250 mM NaCl, 1 mM EDTA, 0.1% 
Triton X-100), the protein was eluted with a gradient of wash buffer now also containing 
80 to 500 mM imidazole. The eluted protein was dialyzed in 25 mM Tris-HCl pH 8.0, 5 
mM NaCl, 5 mM DTT overnight. Then His-NEDD4-1 was further purified by FPLC using 
an anion exchange MonoQ column with the gradient of 5 to 500 mM NaCl added to the 
dialysis buffer over 240 column volumes. Fractions corresponding to the desired protein 
were verified by SDS-PAGE, and highly purified fractions were combined. To the 
combined fractions, 10% glycerol was added and then the protein was concentrated to 
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5mg/ml. The purified protein was flash frozen, and stored in aliquots at -80 °C. The yield 
of His-NEDD4-1 is around 5mg/L culture.   
 
3.2.5  In vitro ubiquitination assay: 
The in vitro ubiquitination reaction was carried out in microcentrifuge tubes in 
volumes of 20 to 50 μL containing 40 mM Tris-HCl pH 7.5, 50 mM NaCl, 2 mM DTT or 
0.5 mM TCEP, 5 mM MgCl2, with 5 mM ATP, 100 μM ubiquitin, 50 nM E1 protein, 1 μM 
E2 protein, 1 μM E3 protein, and 1 or 10 μM PTEN. The reaction mixture without E1 
protein was pre-incubated at 30 °C for 20 minutes and then the reaction was initiated by 
adding the E1. To quench the reaction, an aliquot of the reaction mixture was mixed with 
SDS loading dye at different time points and boiled for 5 minutes. The samples were 
then run out on SDS-PAGE, and stained using a Colloidal Blue Staining Kit following the 
manufacturer’s protocol.  In addition, samples were also analyzed using western blotting 
with an anti-PTEN antibody. The quenched reaction samples containing 50 ng of PTEN 
were loaded on to 10% SDS-PAGE. The protein was then transferred to nitrocellulose 
membranes using the iBlot Dry Blotting system (Thermo Fishier). The membranes were 
blocked with 5% BSA in TBST buffer for 30 minutes, and then incubated with anti-PTEN 
antibody (1:1000 dilution) at 4 °C overnight. Afterwards, the membranes were washed 
with TBST and probed with HRP-conjugated anti-mouse secondary antibody at 1:10000 
dilution. The bands were detected by chemiluminascence using an ECL western blotting 
detection kit from GE Healthcare. All assays were repeated on at least two independent 
occasions with results and replicates showing similar results.  
 
3.2.6  Single-turnover WWP2 ubiquitin transfer assay: 
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These experiments were based on previously reported methods.(189) Reaction 
mixtures containing 40 mM Tris-HCl pH 7.5, 0.5 mM TCEP, 1 mM MgCl2, 1 mM ATP, 
100 μM wild-type ubiquitin, 0.5 μM E1 protein, 5 μM E2 protein, and 2.5 μM WWP2 in a 
volume of 40 µL were incubated at 30 ℃  for 10 minutes.  Then 1 μM apyrase was added 
to the reaction mixtures, and they were incubated at 30 °C for 1 minute, followed by 
addition of 1 µM PTEN. The final volume of the reactions was adjusted to 50 µl. Aliquots 
of the reaction mixture were quenched at different time points after adding PTEN. The 
samples were analyzed by western blot using an anti-PTEN antibody as described 
above. 
 
3.2.7  GST-WWP2 pulldown assay of PTEN forms: 
Non-phosphorylated or tetra-phosphorylated PTEN (1 µM) was mixed with or 
without 1 µM GST-WWP2 in 25 mM Tris pH 7.5, 50 mM NaCl, 5 mM DTT, and 10 µL 
glutathione agarose in a total volume of 100 µL. The mixture was incubated at 4 °C with 
gentle agitation overnight. Afterwards, the glutathione agarose was washed with 1 mL 
wash buffer (25 mM HEPES pH 7.5, 250 mM NaCl, 0.1% Triton X-100) three times. 20 
µl SDS loading dye was added to the resin, and the mixture was then boiled for 5 
minutes. The samples were then analyzed by western blot using an anti-PTEN antibody 
as described above.  
 
3.2.8  Data analysis: 
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To quantify the rate of the ubiquitination reaction, the PTEN band was quantified 
by densitometric analysis using Image J software, and the rate of decrease of 
unmodified and phosphorylated PTEN (µM/min) was calculated. 
 
3.2.9  Enzymatic digestion: 
Approximately 2.5 μg of protein from the PTEN ubiquitination reactions was 
separated via SDS-PAGE and visualized with coomassie blue staining. Protein bands of 
interest were excised, cut into 1 × 1 mm pieces and dehydrated with methanol for 5 min. 
The gel pieces were then washed as follows:  1 x 5 min with 30% methanol/70% water, 
2 x 10 min with water, and 3 x 10 min with 100 mM ammonium bicarbonate 
(NH4HCO3)/30% acetonitrile. Gel pieces were dried in a SpeedVac. Protein disulfide 
bonds were reduced with 10 mM tris(hydroxypropyl)phosphine (TCEP) in 100 mM 
NH4HCO3 for 60 min at 56 °C, followed by alkylation with 55 mM 2-chloroacetamide in 
100 mM NH4HCO3 for 45 min at room temperature in the dark. The gel pieces were 
washed with 100 mM NH4HCO3 for 15 min and dehydrated with acetonitrile followed by 
complete drying in a SpeedVac. Gel pieces were rehydrated in trypsin solution (15 ng/µL 
trypsin in 50 mM NH4HCO3) on ice for 45 min. Excess trypsin solution was discarded, 
replaced with 50 mM NH4HCO3 and incubated overnight at 37 °C. Digestion buffer was 
collected and saved. Peptides were extracted once with 50 mM NH4HCO3, once with 
acetonitrile and twice with 5% formic acid in 50% acetonitrile; each extraction was 
performed by incubating at 37 °C for 15 min with vortexing. All supernatants were 
combined and dried in a SpeedVac. The samples were re-constituted in 50 µL AspN 
reaction buffer (50 mM Tris-HCl, 2.5 mM ZnSO4 pH8) and 12.5 ng/µl AspN was added 
for overnight digestion at 37 °C. Digestion reactions were stopped by the addition of 50 
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µl 0.2% trifluoroacetic acid, and the samples were de-salted using C18 STAGE 
Tips.(190) The samples were re-constituted in 0.2% formic acid in water prior to LC-
MS/MS analysis, and one-third of each sample was injected. 
 
3.2.10  Liquid chromatography-tandem mass spectrometry (LC-MS/MS): 
Chromatographic separation was performed using a Dionex Ultimate 3000 
RSLCnano system (Thermo Scientific) with a 75 µm x 15 cm Acclaim PepMap100 
separating column (Thermo Scientific) protected by a 2 cm guard column (Thermo 
Scientific). The mobile phase flow rate was 300 nL/min and consisted of 0.1% formic 
acid in water (A) and 0.1% formic acid, 95% acetonitrile (B). MS analysis was performed 
using an LTQ Orbitrap Velos Pro mass spectrometer (Thermo Scientific). The spray 
voltage was set at 2.2 kV. Orbitrap spectra were collected from 400-1800 m/z at a 
resolution of 30,000 followed by data-dependent HCD MS/MS (at a resolution of 7500, 
collision energy 35%, activation time 0.1 ms) of the 10 most abundant ions using an 
isolation width of 2.0 Da. Charge state screening was enabled to reject the generation of 
MS/MS spectra for unassigned and singly charged precursor ions. A dynamic exclusion 
time of 40 sec was used to discriminate against previously selected ions. Data were 
searched using SEQUEST in Proteome Discoverer v. 1.3 (Thermo Scientific) against a 
Homo sapiens PTEN UniProt database (UniProt accession # P60484). Database search 
parameters were as follows: enzyme – non-specific (to allow for combined trypsin and 
AspN cleavage); precursor mass tolerance – 10 ppm; fragment ion tolerance – 0.03 Da; 
static modification – Cys carbamidomethylation; variable modifications – Met oxidation, 
Lys ubiquitination and acetylation, and Ser/Thr/Tyr phosphorylation. The data were 
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filtered using a 1% false discovery rate threshold and a maximum peptide rank of 1. All 
MS/MS spectra assigned to modified PTEN peptides were manually inspected. 
 
3.3  Results 
3.3.1  Ubiquitination of n-PTEN by NEDD4-1, WWP2, and XIAP 
For these studies, we prepared 4p-PTEN and n-PTEN using expressed protein 
ligation as described previously.(19)  In this method, aa1-378 of PTEN is prepared as a 
thioester via an intein using a baculovirus expression system, and this is 
chemoselectively ligated to N-Cys containing synthetic peptides aa379-403 with or 
without phosphorylations at Ser380, Thr382, Thr383, and Ser385.  These are wild-type 
in sequence except for the presence of a Y379C mutation necessitated by the ligation 
process which as reported previously does not alter the activity of PTEN.(19)  These 
semisynthetic PTEN proteins were shown to be >90% pure (see Figure 14).  As shown 
previously,(19) the unligated PTEN forms run just below the ligated forms on SDSPAGE 
and so the high purity of the semisynthetic PTENs,  is achieved after anion exchange 
chromatography.  NEDD4-1 protein was also prepared in a baculovirus expression 
system and contains an N-terminal His6 tag that was used in Ni resin affinity 
chromatography for purification (see Figure 14).  WWP2 was prepared as a GST-fusion 
protein using an E. coli expression system and purified by glutathione affinity 
chromatography (see Figure 14).  XIAP was obtained from commercial sources as a 
purified recombinant protein.   
 Ubiquitination experiments with WWP2 were performed with 50 nM E1 ubiquitin 
activating enzyme, 1 µM UbcH5c (E2 ligase), 1 µM WWP2 (E3 ligase), 1 µM n-PTEN, 
100 µM ubiquitin, and 5 mM MgATP.  We monitored the ubiquitination using a 
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combination of both coomassie stained SDS-PAGE as well as western blots with anti-
PTEN Ab. (Figure 15) The reaction mixture's multi-band/streaking pattern readily 
visualized by both methods was attributed to various levels of ubiquitin and polyubiquitin 
chain attachment catalyzed by WWP2.  There was a clear increase of ubiquitination with 
time over the course of the reaction and the non-ubiquitylated n-PTEN was largely 
depleted after 60 min under these conditions (see Figure 15).  WWP2, E2, E1, and ATP 
were each necessary for the reaction to occur as their omission prevented detectable 
ubiquitination.  In the higher molecular weight region of the coomassie stained SDS-
PAGE, auto-ubiquitination of WWP2 was also readily detected. (Figure 15A,B). Using a 
higher concentration of n-PTEN (10 µM) relative to WWP2 (1 µM), perhaps better 
approximating steady-state conditions, the rate of depletion of n-PTEN was reduced and 
had a half-life of about 1 h (Figure 15D). 
 NEDD4-1 (1 µM) was also tested as an E3 ligase with n-PTEN and showed an 
ability to ubiquitylate PTEN, although at a slower rate relative to that of WWP2 (Figure 
16A,B). Given the complexity of the reactions and the wide range of product 
distributions, it is difficult to precisely quantify the relative rates but monitoring depletion 
of the unmodified PTEN suggests a ~4-fold difference.  In contrast to NEDD4-1 and 
WWP2, we were unable to detect n-PTEN ubiquitination with XIAP (Figure 16). We are 
uncertain why XIAP, though undergoing autoubiquitination in our hands, was inactive 
with PTEN in this assay. However, given the measurable rates with NEDD4-1 and 
WWP2, we elected not to pursue further experiments with XIAP. 
 










Figure 14: Purified proteins (n-PTEN, 4p-PTEN, WWP2, NEDD4-1) prepared in this study (SDS-PAGE 






Figure 15: In vitro ubiquitination assay of n-PTEN and 4p-PTEN by WWP2.  (A) In vitro ubiquitination assay 
for n-PTEN. The reaction was carried out in the presence of 5 mM ATP, 100 μM wild-type ubiquitin, 50 nM 
E1, 1 μM E2 (UbcH5c), 1 μM WWP2, and 1 μM n-PTEN in  assay buffer with 40 mM HEPES pH 7.5, 5 mM 
MgCl2. The reaction was quenched at 2.5, 5, 15, 30, 60 minutes.  Negative controls lacking in ATP, 
ubiquitin, E1, E2, E3 or PTEN were assayed respectively. The samples were resolved by SDS-PAGE, and 
the gel was stained with colloidal blue. (B) In vitro ubiquitination assay for 4p-PTEN. The reaction was 
carried out for 4p-PTEN using the same conditions as in Fig. 14A. (C) n-PTEN and 4p-PTEN ubiquitination 
analyzed by western blotting using anti-PTEN antibody. E2 was added to these experiments but the minus 
E2 conditions were not shown in this blot.  (D) In vitro ubiquitination assay for n-PTEN and 4p-PTEN. The 
reaction conditions were the same as in Fig. 14A except that 10 μM PTEN was used instead of 1 μM. 
Ubiquitination of PTEN at time points 0, 0.5, 1, and 2 hours was analyzed by colloidal blue staining. (E) 
Quantification of the rate of PTEN ubiquitination. The ubiquitination assay carried out in Fig. 14D was 
quantified by measuring the decrease of non-ubiquitylated PTEN band intensities and calculating the 















We then investigated the ubiquitination of 4p-PTEN by WWP2 and NEDD4-1.  
Whereas, the rate of ubiquitination of 4p-PTEN by NEDD4-1 was similar to that of its 
reaction with n-PTEN substrate (Figure 16), WWP2 showed a marked reduction in its 
ubiquitination of 4p-PTEN (Figure 15).  In principle, this rate reduction of WWP2 
ubiquitination of 4p-PTEN could be caused by an interference with steps up to and 
including E2's ubiqutyl-transthioesterification loading of E3. This was explored in two 
ways.  First, we examined the WWP2/4p-PTEN reaction in the presence of an 
alternative E2 enzyme, UbCH7, in place of UbCH5c. We observed that UbCH7 could 
work in concert with WWP2 to ubiquitylate n-PTEN and 4p-PTEN, but this system 
showed a similar drop in efficiency with 4p-PTEN substrate relative to that involving 
UbCH5c (Figure 17A). These results suggest that the differences in WWP2 
ubiquitination between 4p-PTEN and n-PTEN are not related to specific interactions 
between the E2 UbCH5c and E3 WWP2. To examine this further, we performed a single 
turnover experiment in which WWP2 was charged by the E1 and E2 and then ATP is 
cleared from the reaction by apyrase-mediated degradation.(189)   The removal of ATP 
at this stage prevents recharging of the E3-ubiquityl thioester after it transfers its 
ubiquitin to PTEN.  In this way, one can more specifically monitor the kinetics of the 
specific step involving the transfer of ubiquitin from WWP2 to PTEN. In this experiment, 
we showed that n-PTEN is still preferentially ubiquitylated over 4p-PTEN by WWP2 
(Figure 17B).  These results suggest that the specific enzymatic step that involves 
transfer of ubiquitin from WWP2 to PTEN is affected by PTEN phosphorylation. 
 The above observations suggest that the tetraphosphorylation of PTEN may 
directly disrupt WWP2-mediated ubiquitination of the PTEN protein by weakening the 
interaction between the WWP2 and PTEN proteins.  To assess this possibility, we 









Figure 16: In vitro ubiquitination assay of n-PTEN and 4p-PTEN by NEDD4-1 and XIAP. (A) The reaction for 
n-PTEN and 4p-PTEN ubiquitination by NEDD4-1 was carried out with 5 mM ATP, 100 μM wild-type 
ubiquitin, 50 nM E1, 1 μM E2 (UbcH5c), 1 μM NEDD4-1 and 10 μM PTEN, for 0, 0.5, 1, 2, and 4 hours. The 
samples were analyzed by colloidal blue staining. (B) 1 μM n-PTEN and 4p-PTEN ubiquitination by NEDD4-
1 under the same reaction conditions was analyzed by western blotting using anti-PTEN antibody. (C) The 
ubiquitination of n-PTEN and 4p-PTEN by XIAP was analyzed by colloidal blue staining. The reaction 
mixture containing 100 μM wild-type ubiquitin, 50 nM E1, 1 μM E2 (UbcH5c), 1 μM XIAP and 1 μM PTEN 
was quenched at 0, 1, 2, and 4 hours and analyzed by colloidal blue staining. (D) Ubiquitination of n-PTEN 


















Figure 17: (A) In vitro ubiquitination assay of PTEN by WWP2 using a different E2. The reaction conditions 
were the same as in Figure 2D except that the E2 was UbcH7 instead of UbcH5c. The samples were 
analyzed by colloidal blue staining. (B) Single turnover assay to measure ubiquitin transfer from WWP2 to n-
PTEN and 4p-PTEN was carried out by charging WWP2 with ubiquitin and then adding PTEN after depletion 









resin, and these were incubated with either n-PTEN or 4p-PTEN proteins.  After 
washing, the glutathione resin was denatured with SDS and the PTEN was analyzed by 
western blot using anti-PTEN Ab, revealing that n-PTEN was more efficiently pulled 
down by WWP2 compared with 4p-PTEN (Figure 18). These findings suggest that 
tetraphosphorylation of PTEN does indeed reduce its affinity for WWP2 and this likely 
contributes to 4p-PTEN's diminished ubiquitination by WWP2 compared with n-PTEN. 
 
3.3.3  Site-specificity of WWP2 and NEDD4-1 mediated PTEN ubiquitination 
We next analyzed the Lys sites of ubiquitination by WWP2 and NEDD4-1 using 
mass spectrometry.   In these experiments, n-PTEN was exposed to the E3 ligases for 6 
h using Lys-free ubiquitin.  Although Lys-free ubiquitin compared with natural ubiquitin is 
less efficiently processed by WWP2 with a rate now similar to NEDD4-1 (Figure 19), its 
use significantly simplified the analysis since it prevented polyubiquitin chain formation.  
The reaction mixtures were run out on SDS-PAGE, subjected to in-gel enzymatic 
digestion and analyzed using liquid chromatography-tandem mass spectrometry (LC-
MS/MS). To ensure the maximum sequence coverage of PTEN for these experiments, 
thereby optimizing the mass spectrometric detection of all the potential PTEN Lys 
ubiquitination sites, sequential enzymatic digestion was conducted with trypsin followed 
by AspN. Of the 34 PTEN Lys residues, 29 were covered among the identified peptides 
from the NEDD4-1 ubiquitination experiment, and 25 were covered among the identified 
peptides from the WWP2 ubiquitination experiment. The total PTEN sequence coverage 
was 91.3% and 79.2% for the NEDD4-1 and WWP2 experiments, respectively (Figure 
20A). As an indication of the comprehensive PTEN sequence coverage for the NEDD4-1 













Figure 18: GST pull-down assay of WWP2 and PTEN. (A) 1 μM GST-WWP2 or GST and 1 μM n-PTEN or 
4p-PTEN were incubated with glutathione agarose resin overnight. The pull-down of PTEN by WWP2 was 
analyzed by western blotting using anti-PTEN antibody. (B) Quantification of 4p-PTEN relative to n-PTEN 
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Figure 19: In vitro ubiquitination assay of n-PTEN with wild-type (wt-Ub) or lysine free ubiquitin (K0-Ub). (A) 
The ubiquitination reaction was carried out in 40 mM Tris-HCl pH 7.5, 5 mM MgCl2, 5 mM ATP, 50 nM E1, 1 
μM E2, 1 μM WWP2, 10 μM n-PTEN, with 100 μM wt-Ub or K0-Ub. The reactions were quenched at 0, 0.5, 
2, 4, and 6 hours and analyzed by colloidal blue staining, and the reaction with K0-Ub at 6 hours was subject 
to mass spectrometry analysis. (B) Same in vitro ubiquitination conditions as in Fig. 6A assay using wt-Ub or 







 acids, which rendered them below the m/z detection range of the mass spectrometer 
used for this study.  
 A representative MS/MS spectrum of an ubiquitylated peptide (Ub-Lys322) is 
shown in Figure 20B.  A total of 11 ubiquitination sites were identified in the NEDD4-1 
experiment compared to 6 in the WWP2 experiment (Fig. 20A). The PTEN ubiquitination 
sites that were shared by the two E3 ligases include: Lys6, Lys80, Lys164, Lys237, 
Lys330, and Lys402.  These Lys sites are relatively broadly distributed throughout the 
PTEN proteins and its major domains, PTPase, C2, and C-terminal regulatory domain 
(see Figure 6A).  It should be noted that of the 5 ubiquitination sites that were identified 
exclusively in the NEDD4-1 experiment, only 1 of these Lys residues (Lys349) was in a 
region of PTEN that was not identified in the WWP2 experiment. With the exception of 
Lys349, each of the peptides containing the putative Lys ubiquitination sites were also 
identified in their unmodified forms.  Of the 6 ubiquitination sites that were identified in 
common between the NEDD4-1 and WWP2 experiments, only Lys402 appears to be 
preferentially ubiquitylated by NEDD4-1 as indicated by the greater spectral counts of 
the peptides containing this ubiquitylated residue (Fig. 20C).  The 5 ubiquitin sites only 
observed with NEDD4-1 included Lys289, Lys322, Lys332, Lys342, and Lys349.  Each 
of these sites occur in the C2 domain.  Interestingly, of the 4 known PTEN ubiquitin sites 
(Lys13, Lys66, Lys80, Lys289) listed in Phosphosite plus 












Figure 20: Mass spectrometric identification of n-PTEN. (A) PTEN sequence coverage. Boxed, shaded 
regions indicate identified peptides. Boxes shaded in gray with solid outlines indicate regions identified in 
common between the NEDD4-1 and WWP2 experiments. Boxes shaded in blue with dashed outlines 
indicate regions that were only identified in the NEDD4-1 experiment. Bold, red - identified sites of Lys 
ubiquitination. Bold, purple – sites of Lys ubiquitination identified only in the NEDD4-1 experiment. (B) 
Representative MS/MS spectrum of the peptide containing Ub-Lys 322. (C) Relative abundance of PTEN 











3.4  Discussion 
Because of PTEN's major role as a tumor suppressor PIP3 phosphatase, 
understanding how PTEN's cellular stability is controlled may offer new directions for 
therapeutic intervention.  These studies have confirmed the ability of both WWP2 and 
NEDD4-1 to ubiquitylate PTEN using enzymatic assays with purified proteins, although 
WWP2 appeared more robust as a PTEN E3 ligase in our hands.  We were unable to 
demonstrate that XIAP serves as a PTEN E3 ligase, but we cannot rule out that other 
factors in the cell may facilitate it's potential to ubiquitylate PTEN. 
 We were especially interested in how phosphorylation of PTEN on a cluster of C-
terminal Ser/Thr residues 380,383,383, and 385 might influence its potential for 
ubiquitination, as it had been proposed that this phosphate cluster can increase PTEN's 
cellular half-life.(20)  Using tetraphosphorylated PTEN we found that such 
phosphorylation antagonizes ubiquitination by WWP2 but not NEDD4-1.  Coupled with 
WWP2's greater enzymatic efficiency than NEDD4-1 as a PTEN E3 ligase, these results 
suggest that WWP2 may be dominant in governing PTEN's cellular degradation when 
PTEN is non-phosphorylated (Figure 21). Perhaps NEDD4-1's more significant control of 
PTEN's stability occurs when PTEN exists in its phosphorylated state, although more in 
vivo experiments will be needed to probe this possibility. 
 The precise mechanism of how phosphorylation of PTEN inhibits its 
ubiquitination by WWP2 is uncertain, however, it is improbable that the Ser/Thr 
phosphates are impeding Lys targeting through proximity-induced obstruction as most of 
the ubiquitination sites are remote from the C-terminal tail and are spread throughout 
PTEN.  The weakening of the WWP2-PTEN interaction observed by pull-down assays 
likely contributes to the reduced ubiquitination efficiency.  Such weakened interaction 












interaction would be less available to WWP2 binding.(19) Perhaps NEDD4-1 binds to 
PTEN in a different fashion than WWP2 interacts with PTEN, and is thus less affected by 
PTEN phosphorylation.  Indeed, it has been reported that NEDD4-1 interacts with PTEN 
in a WW2 motif-independent manner.(17) Further evidence for this appears to come 
from the enhanced targeting of the PTEN C2 domain Lys sites for ubiquitination by 
NEDD4-1 vs. WWP2.  
 It is also possible that phosphorylation of PTEN, by virtue of its effects to diminish 
PTEN membrane binding, may also protect PTEN from membrane associated E3 
ligases.(191)  The combination of cytosolic-nuclear localization of 4p-PTEN and 4p-
PTEN's intrinsic resistance to WWP2-catalyzed ubiquitination could synergize to 
stabilize PTEN in cells.  It is not yet clear which of the large number of ubiquitination 
sites identified here may be most physiologically relevant.  It seems likely that the 
majority of them, if they occur in the cell would help target PTEN toward the proteasome, 
but if not, they would likely interfere with PTEN's normal enzymatic function. 
 Prior studies have validated 4p-PTEN's reduced PIP3 phosphatase activity 
relative to n-PTEN.(19)  It is therefore somewhat paradoxical that tetraphosphorylation of 
PTEN, which inhibits its PIP3 phosphatase activity, also promotes a longer cellular half-
life for the protein.  We speculate that these apparently conflicting properties associated 
with phosphorylation of PTEN allow for a fine-tuning of signaling that maintain PIP3 
levels in a precise range.  This regulatory mechanism also can allow for strict kinetic 
control so that after PTEN is turned on by dephosphorylation and PIP3 levels drop, 





Chapter 4: Autoinhibitory Mechanisms for the HECT E3 Ligases 
 
4.1  Introduction 
HECT domain ubiquitin transferases (E3 ligases) catalyze the Lys ubiquitination 
of numerous cellular proteins and are critical for protein homeostasis and cell signaling 
(50, 82).  Like all E3 ligases, HECT enzymes are activated by the participation of 
upstream E1 and E2 enzymes.  In contrast to the RING family of E3 ligases which have 
an indirect role in ubiquitin bond formation, HECT domains have an active site Cys that 
is charged with ubiquitin by the E2.  The HECT thioester intermediate directly 
ubiquitinates target proteins and itself on Lys residues.  Because of their direct role in 
catalysis, it is presumed that HECT E3 ligases must be held in check to prevent both 
excessive target ubiquitination as well as self-destruction by autoubiquitination (50, 192). 
  Of the 28 human HECT domain E3 ligases, the most intensively studied 
comprise the 9 members of the NEDD4 family (Figure 22) (50, 60, 82).  Members of the 
NEDD4 family include WWP2, WWP1, ITCH, and NEDD4-1 and these E3 ligases target 
for destruction key signaling molecules and transcription factors (50, 79, 81-83). 
Abnormal activities of NEDD4 E3 ligases are connected to cancer, immune disorders, 
and other diseases (50, 79, 81-83, 192).  The NEDD4 family proteins each contain an N-
terminal C2 domain followed by two to four WW domains and culminate in a C-terminal 
catalytic HECT domain (Figure 22 and Figure 24A) (50).  The C2 and WW domains have 
been implicated in substrate selectivity and catalytic regulation of NEDD4 E3 ligases 











Figure 22: Phylogenetic tree of the NEDD4 HECT E3 ligase family generated using PAM250. These 






 Prior structural studies have revealed that HECT domains contain a larger N-lobe 
which can interact with E2 proteins and a smaller C-lobe that contains a catalytic Cys 
residue involved in ubiquitin transfer (50).  In addition, several HECT family members 
have been shown to possess an N-lobe ubiquitin binding exosite (68, 69, 73).  Remote 
from the ubiquitin substrate binding site in the HECT C-lobe, this exosite has been 
characterized structurally and shown to engage a distinct ubiquitin molecule in HECTs 
and this can catalytically activate these E3 ligases (68, 69, 71-73).  The N- and C-lobes 
are connected by a hinge loop and the HECT domains have been captured in two 
conformational states, a ground state T-shape (65, 73) and a catalytically proficient L-
shape (67, 73).   The dynamic inter-conversion of the T-shape and L-shape HECT 
conformations is necessary for turnover, but what governs this transition is uncertain.  
Interactions with C2 domain, WW domains, and various post-translational modifications 
have each been proposed to influence HECT domain catalytic activity but biochemical 
details for this have generally been lacking (77, 82, 100, 137, 139-142). 
 Here we investigate the regulation of WWP2, a NEDD4 family member that has 
been shown to ubiquitinate and target for removal the key tumor suppressor PTEN and 
the important stem cell-related transcription factor OCT4 (27, 78).  WWP2 contains four 
WW domains (WW1-WW4) and is most closely related to the NEDD4 family members 
WWP1 and ITCH which have been linked to cancer and immunologic control (60, 79, 
194).  Our studies have revealed an unanticipated autoinhibitory module centrally 
located in WWP2, WWP1, and ITCH between the WW2 and WW3 domains, and below 





4.2  Methods 
4.2.1  Plasmids and reagents 
The pGEX6p-2 human WWP2 plasmid was provided by Dr. Wenyi Wei at Beth-
Israel Deaconess Medical Center. Human WWP1 cDNA was purchased from Genscript, 
and subcloned into pGEX6p-2. pGEX-KG containing human ITCH was obtained from Dr. 
Allan M. Weissman at National Cancer Institute(195). Human NEDD4-1 cDNA was 
provided by Dr. Xuejun Jiang at Sloan-Kattering Mommerial Cancer Center. Mutations 
and truncations in WWP2, WWP1, and ITCH were introduced by Quik-Change (Agilent) 
or restriction enzyme based cloning. Purified wild-type ubiquitin, human ubiquitin-
activating enzyme UBE1, and human ubiquitin-conjugating enzyme UbcH5c were 
prepared as described previously (188). The Colloidal Blue Staining Kit was purchased 
from Invitrogen. All other reagents were commercially purchased with the highest quality 
from either Sigma or Fisher. 
 
4.2.2  Protein expression and purification 
BL-21 Codon Plus cells were transformed with the pGEX6p-2 plasmid expressing 
full-length WWP2, WWP1, ITCH, or the different mutations or truncations, initially as N-
terminally modified GST-fusion proteins. The transformed cells were cultured in LB 
medium at 37 °C to reach the optimal density (OD600=0.6) in a shaker incubator grown 
on a 1 L scale. Protein expression was induced by 0.25 to 0.5 mM IPTG at 16 °C for 20 
hours. The cells were resuspended in 25 mL lysis buffer (25 mM Tris-HCl pH 8.0, 250 
mM NaCl, 1 mM phenylmethylsulfonyl fluoride (PMSF) and 1x Roche cocktail protease 
inhibitors) and were lysed by french press. The cell lysate was loaded on glutathione 
agarose followed by washing with 25 mM Tris-HCl pH 8.0, 250 mM NaCl, and 0.1% 
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Triton X-100. The desired GST-tagged protein was eluted using 10 mL 25 mM Tris-HCl 
pH 8.0, 250 mM NaCl containing 50 mM reduced glutathione at pH 8.0. The eluted 
fractions were combined and dialyzed against a buffer consisting of 25 mM Tris-HCl pH 
8.0, 250 mM NaCl, 10 mM BME, and the protein was treated with PreScission protease 
at 4 °C overnight to cleave the GST tag. Afterwards, the mixture of GST and cleaved 
protein was loaded to glutathione agarose again to remove the GST. The protein was 
concentrated and then loaded on a size exclusion column Superdex 200 (GE 
Healthcare) with a buffer containing 25 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM DTT 
(dithiothreitol). The corresponding purified fractions assessed by Coomassie stained 
SDSPAGE were combined and glycerol was added to a final concentration of 10% v/v. 
The purified protein was concentrated to 1 to 10 mg/mL, flash frozen, and stored at -
80ºC. 
 
4.2.3  Peptide synthesis 
The 2,3-linker peptides (+/-369-phospho) of sequence (n-
TAEYVRNYEQWQSQRNQLQGAMQHFSQRFLYQSS-c) were prepared using the Fmoc 
solid phase synthesis straetgies with a PS3 peptide synthesizer from Protein 
Technologies (Tuscon, AZ). The peptides were purified by reversed phase HPLC on a 
C-18 column using a water:acetonitrile gradient (containing 0.05% trifluoroacetic acid) to 
>90% and the correct structures confirmed by MALDI mass spectrometry (Figure 23) 








Figure 23: Mass spectrum of peptides used in this study. (A) Mass spectrum of nonphosphorylated 2,3-linker 
peptide with a C-terminal amide. The calculated mass: m/z 4209. (B) Mass spectrum of Tyr369 
phosphorylated 2,3-linker peptide with a C-terminal amide. The calculated mass: m/z 4289. (C) Mass 
spectrum of Tyr369 phosphorylated 2,3-linker peptide with a C-terminal N-acyl-benzimidazolinone (Dbz) 
used for protein semisynthesis. The calculated mass: m/z 2594. Note that the m/z 2436 is believed to be 
mass spec induced fragmentation leading to loss of the Dbz group.  However, even this mass is related to 










4.2.4  In vitro ubiquitination assays 
The in vitro ubiquitination reactions were carried out in microcentrifuge tubes in 
final volumes of 20 µL containing 40 mM Tris-HCl pH 7.5, 50 mM NaCl, 0.5 mM TCEP, 5 
mM MgCl2, with 5 mM ATP, 100 µM ubiquitin, 50 nM E1 protein, 1 µM E2 protein, 1 µM 
E3 protein. The reactions were initiated by adding the E1 and carried out at 30 °C. At 
different time points, the reactions were quenched by mixing 4 µL aliquots of the reaction 
mixture with SDS loading dye and boiled for 5 minutes. The samples were then run out 
on SDSPAGE, and stained using a Colloidal Blue Staining Kit following the 
manufacturer’s protocol. The unmodified E3 protein bands at the time points shown in 
the figures were quantified using ImageJ densitometry and normalized to the zero time 
points.  Note that this quantification method monitors the disappearance of the 'starting 
material' but does not distinguish among the range of ubiquitinated products formed, and 
this product distribution pattern varies among different mutants. All assays were 
performed on at least two independent occasions with replicates showing similar results. 
 
4.2.5  Generation of fluorescein labeled ubiquitin variants (UbF1 and UbF2) 
Wild-type human ubiquitin DNA was sub-cloned into pGEX6p-2 and mutated to 
UbV P2.3 and UbV NL1 (69) using Quik-Change. In addition, Ser57 was replaced with 
Cys by Quik-Change mutagenesis. GST-UbV S57C was expressed by BL21 Codon Plus 
cells as described for WWP2. The GST-fusion mutant ubiquitin proteins were purified 
using glutathione agarose and eluted with 50 mM reduced L-glutathione. After cleavage 
of GST tag by PreScission protease, the proteins were further purified by size exclusion 
chromatography using Superdex 75 column (GE Healthcare) with PBS buffer. Purified 
UbV S57C proteins (2 mg) were mixed with 10-fold molar excess of 5-
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iodoacetamidofluorescein (Thermo) in PBS buffer containing 5 mM EDTA in 2 mL at 
room temperature for 4 hours in the dark. The labeled proteins UbF1 and UbF2 were 
separated from the unreacted reagent by dialysis and size exclusion chromatography 
using the buffer containing 25 mM HEPES pH 7.3, 150 mM NaCl, 1 mM EDTA, 2 mM 
DTT, 5% glycerol. 
 
4.2.6  Fluorescence anisotropy 
UbF1 and UbF2 protein (100 nM) was mixed with the indicated concentrations of 
E3 ligase forms in the buffer (25 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM DTT, 10% 
glycerol) and incubated at room temperature for 20 minutes. Steady-state fluorescence 
anisotropy data were acquired using a FluoroMax-3 spectrofluorimeter (Jobin Yvon 
Horiba) at 23 °C. The excitation wavelength was set to 495 nm and emission was 
measured at 520 nm. Each fluorescence anisotropy data point was measured to high 
accuracy at least three times. The binding curves and Kd values were generated using 
the quadratic-binding fit with the equation Y= Y0 - [(Y0 - Ymax)/(2*Fixed)] * [b - sqrt(b^2 - 
4*X*Fixed)] (b=Kd + X + Fixed, Fixed=0.1). At least two independent replicates were 
carried out for each data set on independent occasions with Kd values in good 
agreement (within 30%). 
  
4.2.7  Crystallization  
The construct, 2,3-linker-HECT865, used for crystallization, contains residues 
369 to 865 whereas aa 399-484, containing the tandem WW3-WW4 domains, has been 
deleted. Purified 2,3-linker-HECT865 was concentrated to 3 mg/mL in a buffer 
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containing 25 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM DTT. Note that WWP2 residues 
866-870 were deleted to facilitate crystallization (65).  Crystals were grown at 20 °C by 
vapor diffusion in hanging drops of 1 µL of protein with 2 µL of reservoir solution 
containing 0.1 M Bis-Tris pH 5.8 to 7.5, 0.2 M MgCl2, 12 to 18% (m/v) PEG3350. 
Clusters of needle crystals were obtained, and crystal morphology and size were 
optimized by microseeding.  
 The WW2-2,3-linker-HECT865 construct contains aa334-865 with the deletion of 
aa399-484. Freshly-purified WW2-2,3-linker-HECT865 was concentrated to 10 mg/mL in 
buffer containing 25 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM DTT, 5% glycerol. 
Crystallization trays were set up using the LCP Mosquito robot (TTP Labtech, Inc) with a 
drop size of 0.3 µL protein with 0.3 µL reservoir solution in 96-well plates in hanging 
drops. Crystals grew at 20 °C and were monitored automatically using a Rock Imager 
and Rock maker system (Formulatrix, Inc., USA). Two conditions resulted in single 
crystals: one condition had 0.1 M potassium thiocyanate, 30% PEG monomethyl ether 
2000 as reservoir solution, and the other condition had 0.1 M MMT (DL-malic acid, MES, 
Tris-base in molar ratio of 1:2:2) pH 6.0, 25% PEG1500 as reservoir. All crystals were 
cryoprotected in the same solution that they were grown and stored in liquid nitrogen for 
data collection. 
 
4.2.8  Data Collection and Structural determination 
Diffraction data of 2,3-linker-HECT and WW2-2,3-linker-HECT (PEG 1500 
precipitant) were collected at ALS beam line 502 on a DECTRIS Pilatus 6M detector 
(wavelength 1.0 Å and temperature 100 K, Table 2).  Diffraction data of WW2-2,3-linker-
HECT using PEG MME 2000 as a precipitant were collected using a Rigaku FR-E 
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SuperBright X-ray generator at a wavelength of 1.5418 Å and recorded on a PILATUS 
2M. All diffraction data were processed, integrated and scaled with HKL-2000 (196).  
 The 2,3-linker-HECT structure was determined by molecular replacement using 
the program AMoRe and the HECT domain of WWP2 (PDB ID 4Y07 )(177) as the initial 
search model. The model was re-built manually with iterative rounds of Coot and refined 
using Refmac5 from the CCP4 suite (197). The final structure, PDB ID 5TJQ, was 
refined to 2.75 Å. Ramachandran plot analysis indicates 4.5 % of outliers, 3.3 % allowed 
and 92.1 % favored residues. The 2 WW2-2,3-linker-HECT structures were determined 
by molecular replacement using PDB ID 5TJQ as a template.  The initial models were 
rebuilt and refined as described previously for PDB 5TJQ. The refined structure with 
disorder the WW2 domain, 5TJ8, has excellent geometry as display by 91.2 % residues 
in preferred and 4.5 % allowed regions. The refined structure with WW2 domain, PDB ID 
5TJ7, has 93.1 % and 3.3 % residues in the preferred and allowed regions respectively. 
All figures were rendered with PyMOL (198). 
R.M.S.D. comparison of the new and prior WWP2 and WWP1 HECT domain structures 
(units in angstroms) 
 1ND7 4Y07 5TJQ 5TJ7 
5TJQ 1.29  0.73 - - 
5TJ7 1.95 1.06 1.44 - 
5TJ8 1.27 0.66 0.95 1.33 
 
 
4.3  Results 




Figure 24: Full-length GST-free WWP2 is autoinhibited. (A) Schematic of WWP2 domains with amino acid 
residue numbers. (B) Ubiquitination assay of GST tagged WWP2 and GST-free WWP2. The reaction was 
conducted at 30 °C in the presence of 5 mM MgCl2, 5 mM ATP, 100 μM wild-type ubiquitin, 50 nM E1, 1 μM 
E2 (UbcH5c), 1 μM E3. The reaction was quenched at 0, 0.5 and 2 hours and samples analyzed by 
SDSPAGE followed by colloidal blue staining. The activity of WWP2 was determined by the time-dependent 
depletion of the unmodified E3 ligase band and the appearance of higher MW bands presumed to represent 
poly-ubiquitination. (C) Ubiquitination assay of full-length WWP2 as GST-WWP2, GST-free WWP2, and 
WWP2 plus GST as an intermolecular mixture. The reaction was conducted in the presence of 5 mM ATP, 
100 μM wild-type ubiquitin, 50 nM E1, 1 μM E2 (UbcH5c), 1 μM GST-WWP2, WWP2 without or with 10 μM 
GST, and 5 μM PTEN, in assay buffer with 40 mM Tris-HCl pH 7.5, 50 mM NaCl, 0.5 mM TCEP, 5 mM 
MgCl2. The reaction was quenched at 0, 0.5 and 2 hour time points. The samples were analyzed by 












In the course of in vitro analysis of full length WWP2 and ubiquitination of its 
protein substrate PTEN (199), we observed that the fusion protein glutathione S-
transferase-WWP2 (GST-WWP2) was a robust catalyst (Figure 24B,C). However, 
proteolytic removal of the GST reduced WWP2's ubiquitin transferase activity toward 
PTEN and itself (Figure 24B,C).  Addition of GST in trans to GST-free full-length WWP2 
failed to restore its activity to the levels observed for the GST-WWP2 fusion (Figure 
24C).  Size exclusion chromatography of GST-free WWP2 showed that it was largely 
monomeric (Figure 25A), and this monomeric form showed low ubiquitin transferase 
activity whereas a small fraction of GST-free full length WWP2 eluted as an oligomeric 
form which appeared to be much more active (Figure 25B).  As GST is an obligate 
dimer, these results suggest that GST-free WWP2 may be subject to allosteric 
intramolecular inhibition, partially relieved by self-interaction, although the structural 
basis for this was unclear.  
 It has been reported that the C2 domain and the WW domains in HECT E3 
ligases (Figure 22 and Figure 24A) may be important for regulating their catalytic 
activities (100, 137-139, 193). To investigate the role of the C2 domain in WWP2, we 
prepared C2 domain-free WWP2 which showed low activity similar to that of full-length 
GST-free WWP2 (Figure 26A).  We note that these WWP2 results differ from findings in 
a previous report (137).  To evaluate the role of the WW domains, we explored the 
effects of a commercially available canonical WW peptide ligand containing a PPXY 
motif (WW peptide), and also made mutations in the WW domain-binding LPXY motifs in 
the WWP2 HECT domain (100). Neither WW peptide addition nor LPXY mutation led to 
altered WWP2 ubiquitin transferase activity (Figure 26B,C), arguing against the 


















Figure 25: Full-length GST-free WWP2 contains autoinhibited monomer and active aggregate. (A) Size 
exclusion chromatography of GST-WWP2 after GST cleavage. The purified GST-WWP2 was treated with 
PreScission protease to cleave the GST tag and then analyzed by FPLC size exclusion chromatography. 
The dotted line trace represents MW standards corresponding to 670, 160, 44 and 29 kDa. The solid line 
trace shows the cleaved GST-WWP2: Peak A-WWP2 oligomer (>670 kDa), Peak B-WWP2 momoner (100 
kDa), and Peak C-GST dimer (55 kDa). (B) Ubiquitination assay of WWP2 monomer and oligomer. The 
reaction was carried out in similar conditions as described in Figure 24B, but with 10 μM PTEN, and the 













    
Figure 26: Analysis of C2 domain and WW domain in the auto-regulation of WWP2. (A) Ubiquitination assay 
of GST-WWP2, Full-length WWP2 (FL-WWP2), and WWP2 △C2. The reaction was conducted in the same 
condition as Figure 24B, and quenched at the times indicated. (B) Ubiquitination assay of full-length WWP2 
containing LPXY motif point mutations.  Both the single and double Y to A mutants were generated. (C) 
Ubiquitination assay of full-length wild-type WWP2 in the presence of the indicated concentrations of PPxY 











 We next introduced a protease site N-terminal to the WW3 domain in WWP2 
(Figure 27A) and determined that the WW3-WW4-HECT protein fragment could partially 
co-elute with the C2-WW1-WW2 fragment by size exclusion chromatography (Figure 
27B,C).  This raised the possibility that interactions between the N-terminal and C-
terminal components of WWP2 might modulate the activity of intact full-length WWP2. 
Consistent with this hypothesis, purified recombinant WWP2 HECT domain and WW3-
WW4-HECT protein showed robust autoubiquitination activity (Figure 27D).  Based on 
these findings, we suspected that the WW1-WW2 moiety was crucial for enforcing 
autoinhibition of WWP2.  However, intermolecular addition of a purified recombinant 
WW1-WW2 protein fragment to WW3-WW4-HECT WWP2 did not inhibit the latter's 
ubiquitin transferase activity (Figure 28). 
 
4.3.2  The WW2-WW3 linker (2,3-linker) as an autoinhibitory module of WWP2   
 Because of the lack of an apparent role for the C2 or WW domains in WWP2 
catalytic regulation, we considered the possibility that the 30 aa WW2-WW3 linker (2,3-
linker), proposed to possess α-helical character by a protein structure prediction 
algorithm (PSIPRED v3.3), might be critical for autoinhibition of WWP2 enzymatic 
activity.  We tested this possibility in several ways.  We prepared purified recombinant 
2,3-linker-WW3-WW4-HECT protein and found that it was less active than the linker-free 
WW3-WW4-HECT WWP2 enzyme form (Figure 29A).  In addition, we showed that a 
synthetic linker peptide (aa362-395) could inhibit WW3-WW4-HECT WWP2 in an 
intermolecular fashion (Figure 29B).  Moreover, genetic deletion of the 2,3-linker from 
full-length untagged WWP2 profoundly (~100-fold) increased its autoubiquitination 







Figure 27: Intramolecular interaction mediates the autoinhibition of WWP2. (A) Schematic diagram showing 
that a TEV protease cleavage site (ENLYFQ/G) was inserted by mutagenesis between residues Ser395 and 
Ala396 just N-terminal to the WW3 domain. This purified TEV-site containing WWP2 protein was cleaved by 
TEV protease into a N-terminal fragment X containing the C2 domain, the WW1 domain, and the WW2 
domain and a C-terminal fragment Y containing the WW3 domain, the WW4 domain, and the HECT domain. 
(B) Size-exclusion chromatogram of the TEV-cleaved WWP2 (solid line trace) superimposed with MW 
standards (dashed line trace). There were two major peaks Peak A (100 kDa) and Peak B (50 kDa). (C) 
Analysis of the chromatography fractions from D. Fractions corresponding to Peak A and Peak B were 
analyzed by SDSPAGE and Coomassie staining. Peak A is the heterodimer of fragment X and Y, and Peak 
B is fragment Y alone. Assignment of the the X fragment band running above the Y fragment band, although 
paradoxical based on their predicted molecular weights, is based on a recombinant standard of Y (data not 
shown). (D) Ubiquitination assay of WWP2 △C2, WW3-WW4-HECT, and HECT. Performed as described in 
Figure 24B and quenched at the times indicated. All the assays were repeated at least twice (n≥2) and 















                         
 
 
Figure 28: Analysis of WW1-WW2 piece in the auto-regulation of WWP2. (A) Coomassie gel of purified 
WW1-WW2 protein. (B) Mass spectrum of the purified WW1-WW2 protein. (C) Ubiquitination assay of 
WW3-WW4-HECT with different concentrations of WW1-WW2. 1, 10 and 30 μM purified recombinant WW1-
WW2 was added to the reaction, and the reaction was conducted in similar condition as described in Figure 















Figure 29: Regulation of WWP2 autoubiquitination activity by WW2-WW3 linker (2,3-linker). (A) 
Ubiquitination assay of full-length WWP2 (FL-WWP2), 2,3-linker-WW3-WW4-HECT and WW3-WW4-HECT 
carried out as in Figure 24B. The reaction for FL-WWP2 and 2,3-linker-HECT was quenched at 0, 30 and 60 
minutes, and that for WW3-WW4-HECT was quenched at 0, 10 and 20 minutes. (B) Ubiquitination assay of 
WW3-WW4-HECT in the presence of 2,3-linker peptide (n-
TAEYVRNYEQWQSQRNQLQGAMQHFSQRFLYQSS-c) carried out as in Figure 24B with 0, 50 and 100 μM 
synthetic 2,3-linker peptide.  (C) Ubiquitination assay of wild-type WWP2 and WWP2 with 2,3-linker deletion 









 One possible mechanism for how the 2,3-linker may inhibit WWP2 catalytic 
activity is by blocking the E2-E3 interaction that is necessary for charging the HECT 
domain with ubiquitin (63). However, the full-length and 2,3-linker-free WWP2 showed a 
similar ~3-fold stimulation of autoubiquitination activity with a 30-fold increase in E2 
concentration (Figure 30A,B) suggesting that the 2,3-linker probably does not modulate 
the E2-E3 interaction.  
 
4.3.3  Structural basis of WWP2 autoinhibition by the 2,3-linker 
 To gain greater insight into the molecular basis of the role of the 2,3-linker, we 
sought to solve the crystal structure of autoinhibited WWP2 construct containing the 2,3-
linker. The trials using the constructs WW1-WW2-WW3-WW4-HECT and 2,3-linker-
WW3-WW4-HECT did not yield any crystal hits. We considered that the WW3-WW4 
piece is not directly involved in the autoinhibition and that it might be flexible which could 
prohibit crystal formation. Therefore, we generated the WWP2 deletion construct with 
deletion of the WW3 and WW4 domains, effectively fusing the 2,3-linker directly to the 
HECT domain. Ubiquitination assay showed this 2,3-linker-HECT construct still 
displayed autoinhibition (Figure 31A). A brief 96-well plate based screen yielded several 
crystallization conditions that generated a cluster of needle crystals, indicating that this 
construct was promising for solving the structure of autoinhibited WWP2. However, 
optimization by varying the precipitant concentrations and buffer pH did not produce 
crystals good enough for data collection.  
We next went on to try to optimize the construct. Our goal was to to find the 











Figure 30: Effect of E2 concentration on the autoubiquitination of WWP2 forms. (A) Ubiquitination assay of 
wild-type full-length WWP2 (FL-WWP2 WT) with two different concentrations of E2. The ubiquitination assay 
was carried out in a buffer containing 40 mM Tris-HCl pH 7.5, 50 mM NaCl, 0.5 mM TCEP, 5 mM MgCl2, 
mixed with 5 mM ATP, 100 μM wild-type ubiquitin, 50 nM E1, 1 μM E3, and 1 μM or 30 μM E2 (UbcH5c). 
The reaction was quenched at 0, 1, 2, and 3 hours. (B) Ubiquitination assay of full-length WWP2 with 2,3-
linker deletion (FL-WWP2 △2,3-linker) with two different concentrations of E2. The reaction was conducted 
in the same condition as panel A, and quenched at 0, 2, 5, and 10 minutes. Replicate assays were 
performed on separate occasions (n=2) and showed similar results, with about 3-fold rate enhancements at 







residues of all the constructs used for crystallization needed to be deleted(177) while the 
constructs used for activity assays had to retain a normal C-terminus since is essential 
for ubiquitin transferase activity(67, 71, 75). As an initial step, I optimized the N-terminal 
part of the construct to delete the redundant residues. The 2,3-linker sequence 
(TAEYVRNYEQWQSQRNQLQGAMQRFSQRFLYQ, from 362 to 393) was differentially 
truncated in the 2,3-linker-HECT construct, and the activity was measured. It was found 
the shortest construct which retained the autoinhibitory activity was the one that started 
form Y365 (data not shown). The original 2,3-linker-HECT construct contained a 22-
amino acid segment between the 2,3-linker and the HECT domain. I then tried to 
optimize this segment to find the shortest linker. I tested a 16-amino acid segment and a 
12-amino acid segment, and it turned out that the 16-amino acid segment-containing 
construct showed similar activity to that of the original 22-amino acid segment-containing 
construct, but the 12-amino acid segment-containing construct showed increased 
autoubiquitination activity (data now shown). Thus, in subsequent screening, we used 
the construct that started with Y365 and contained a 16-amino acid segment between 
the 2,3-linker and the HECT domain. The crystals were successfully optimized with this 
new construct, and we solved the structure (Figure 31B). The X-ray structure of 2,3-
linker-HECT WWP2 (Figure 31B) showed the HECT domain in the T-shape 
conformation, which appeared similar to the known WWP1 and WWP2 HECT domain 
structures (65, 177), but the 2,3-linker was not observed (see Methods for an R.M.S.D. 
comparison of structures).  
To attempt to find the electron density of the 2,3-linker, we employed semi-
synthesis to introduce an iodine-phenylalanine, replacing the Y369 in the 2,3-linker-











                                                       
  
Figure 31: Crystallization of autoinhibited WWP2 HECT domain. (A) Ubiquitination assay of HECT, 2,3-
linker-HECT and WW2-2,3-linker-HECT. Ubiquitination assay was conducted in the same conditions as 
Figure 24B, and the reaction was quenched at 0, 1, 5, and 10 minutes for HECT and 2,3-linker-HECT, and 
at 0, 30, 60, 120 minutes for WW2-2,3-linker-HECT. (B) Crystal structure of 2,3-linker-HECT showing the 
HECT domain of WWP2, the N-lobe in dark grey color, the C-lobe in green, and the hinge loop in magenta. 
(C) Structure of WW2-2,3-linker-HECT crystallized in 0.1 M MMT pH 6.0, 25% PEG1500. The N-lobe of 
HECT domain is in grey, the C-lobe is in green, the hinge loop in magenta, the 2,3-linker in red, and the C-
terminal six residues of the WW2 domain in yellow. (D) Structure of WW2-2,3-linker-HECT crystallized in 0.1 
M potassium thiocyanate, 30% PEG monomethyl ether 2000. The N-lobe of HECT domain is in silver, the C-
lobe in green, the hinge loop in magenta, the 2,3-linker in red, and the WW2 domain in yellow. (E) Electron 













Table 2  Data collection and refinement statistics 
 2,3-linker-HECT  
PDB ID 5TJQ 
WW2-2,3-linker-HECT 
PDB ID 5TJ7 
WW2-2,3-linker-HECT  
PDB ID 5TJ8 
Data collection    
Space group P212121 P1 P212121 
Cell dimensions      
    a, b, c (Å) 61.0, 62.5, 102.3 72.0, 73.9, 82.3    44.2, 89.2, 111.4 
    a, b, g  ()  90.0, 90.0, 90.0 89.9, 89.6, 90.0 90.0, 90.0, 90.0 
Resolution (Å) 50.00-2.75 (2.80-2.75) 50.00-2.60(2.64-2.60)  50.00-2.20 (2.24-2.20) 
Rsym or Rmerge 0.052 (0.42) 0.04 (0.10) 0.07 (0.26) 
I / sI 28.77(2.19) 21.95 (6.42) 31.45 (2.85) 
Completeness (%) 99.1 (98.6) 90.2 (55.1) 92.5 (65.2) 
Redundancy 6.0 (5.2) 2.1 (1.8) 5.3 (2.5) 
Unique Reflections 10,662 47,023 21,431 
Total # Reflections 63,445 90,187 111,903 
    
Refinement    
Resolution (Å) 53.39-2.75 50.00-2.60 69.68-2.30 
No. reflections 10,094 44,712 18,436 
Rwork / Rfree 0.22 (0.34)/0.31 (0.37) 0.21 (0.28)/0.28 (0.39) 0.21 (0.31)/0.31 (0.40) 
No. atoms    
    Protein 3,093 14,925 3,525 (416 aa) 
    Ligand/ion - 3 1 
    Water 11 996 56 
B-factors    
    Protein 88 24 69 
    Ligand/ion - - 59 
    Water 62 36 56 
R.m.s. deviations    
    Bond lengths (Å) 0.011 0.013 0.013 
    Bond angles () 0.003 0.008 0.002 
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which we hypothesized could highlight the location of 2,3-linker. Unfortunately, we were 
still unable to find the electron density of the iodine or the 2,3-linker. 
We found that although the 2,3-linker-HECT construct showed reduced 
autoubiquitination activity relative to the isolated HECT domain, inclusion of the WW2 
domain in a WW2-2,3-linker-HECT construct further intensified autoinhibition, with 
activity comparable to full-length WWP2 (Figure 31A, please note the different time 
scales above the gel). The crystallization of WW2-2,3-linker-HECT construct was 
successful, and we determined the X-ray crystal structures (Figure 31C,D) at 2.8 and 2.3 
Å resolution, respectively (Table 2). The structures of two crystal forms of WW2-2,3-
linker-HECT WWP2 were determined. In one, the complete WW2 domain and 2,3-linker 
was observed (Figure 31D), and in the other, only the C-terminal 6 residues of the WW2 
domain could be resolved, but the rest of the structures including the 2,3-linker and 
HECT domains were nearly identical (Figure 31C). 
 The fold of the WW2 domain shows a characteristic three-stranded β-sheet, and 
interestingly, its interaction with the HECT domain is mediated by its C-terminal 6 
residues, especially Trp358 (Figure 32A), which is mutated in cancer (200). Indeed we 
found that the WWP2 W358L cancer mutant is more active than wt WWP2 (Figure 32B). 
The 2,3-linker forms a 26-residue α-helix that makes extensive interactions with the N-
lobe and C-lobe of the WWP2 HECT T-shape conformation (Figure 31B,C,D,E and 
Figure 33A,D). The helix displays a unique bent conformation and wraps around the 
HECT domain with buried surface area of 1150 A2. The N-terminal residues of the 2,3-
linker and the WW2 domain occupy a site in the HECT N-lobe that is the proposed 
allosteric binding exosite for non-covalently bound ubiquitin (Figure 33B) (69, 73). 
Therefore, in the 2,3-linker bound WWP2 form, it appears that the 2,3-linker would 









Figure 32: Interaction between the C-terminal six residues of the WW2 domain and the HECT domain in 
WWP2, and analysis of Trp358 mutation. (A) Zoom-in structure of the C-terminus of WW2 domain 
illustrating that Trp358 forms pi-stacking/hydrophobic interactions with the side chains of Asn598 and 
Pro599, and Gln359 makes a hydrogen bond with the main chain of Pro574.  (B) Ubiquitination activity of 
WWP2 cancer mutant W358L compared with wt WWP2, performed as described in Figure 24B (n=2, similar 








WWP2 activity. The C-terminal residues of the 2,3-linker are engaged with the hinge-
loop that tethers the WWP2 HECT domain N- and C-lobes (Figure 33D and 33E) (65). 
This 2,3-linker-hinge interaction appears to restrain the flexibility of the C-lobe which is 
necessary for ubiquitin transferase activity (65), locking WWP2 in the T-shape, as the L-
shape conformation would be incompatible with such linker engagement.  
 The autoinhibited WWP2 structure predicts that the affinity of ubiquitin binding to 
the WWP2 exosite (69, 73) in the 2,3-linker-HECT or the WW2-2,3-linker-HECT 
constructs would be reduced relative to that of the isolated WWP2 HECT domain.  To 
investigate this, we prepared a ubiquitin variant (UbF1) engineered to have high affinity 
for the WWP2 exosite (69) and also tagged with fluorescein via Cys alkylation, 
introduced at a ubiquitin surface residue (Ser57) that is remote from its E3 binding 
surface (Figure 34).  Using a fluorescence anisotropy assay, we found that UbF1 had a 
Kd of 0.23 µM for the isolated HECT domain, 0.93 µM for 2,3-linker-HECT and 20 µM for 
WW2-2,3-linker-HECT (Figure 33C).  This progressive loss of affinity for allosteric 
ubiquitin by these WWP2 forms correlates well with the different catalytic activities of 
these three proteins (Figure 31A) and is consistent with the distinct X-ray crystal 
structures of the isolated WWP2 HECT domain and autoinhibited WWP2.  In addition, 
we investigated the conserved hinge residues Met752 and Gln753 that appear to make 
close contacts with the WWP2 2,3-linker amino acids 389-RFLY-392.  It is notable that 
M752T and Q753L WWP2 point mutations have been found in cancer (201, 202).  The 
WWP2 double mutant M752A/Q753A and the single mutant WWP2 M752T both showed 
considerably increased WWP2 autoubiquitination activity relative to wt WWP2 (Figure 
33F).  These mutagenesis results validate the structural model and indicate how cancer 







Figure 33: Structural mechanisms for 2,3-linker mediated autoinhibition of WWP2. (A) Overall structure of 
WW2-2,3-linker-HECT with the HECT domain in an inactive (inverse T-shape) conformation. The WW2 
domain is in yellow, the 2,3-linker is in red, the N-lobe of HECT domain is in silver, the C-lobe of HECT 
domain is in green, and the hinge loop between N and C-lobe is in magenta. (B) A blow-up of the region 
highlighted with a square in Figure 33A showing the ubiquitin-binding exosite in the HECT domain. The 
structure of the WWP2 WW2-2,3-linker-HECT protein is superimposed with the structure of the WWP1 
HECT-UbV P2.3-UbvH7 complex (5HPT). The ubiquitin-binding exosite in the HECT domain is occupied by 
the N-terminus of the 2,3-linker and the WW2 domain. (C) Affinity of fluorescein-labeled UbV P2.3 (UbF1) 
for WWP2 forms HECT, 2,3-linker-HECT, and WW2-2,3-linker-HECT, respectively measured by 
fluorescence anisotropy.  Kd values were obtained using quadratic fits and shown +/-SEM (n=2). (D) 2,3-
linker interacts with the hinge region in WWP2.  WW2-2,3-linker-HECT structure visualized by rotating by 
50° relative to the orientation in Figure 33A. From this perspective, the structure of the WW2 domain 
consisting of three beta strands is clear. The hinge which connects the N- and C-lobes of the HECT domain 
is boxed. (E) A blow-up of the boxed region in Figure 33D illustrates the interaction between the hinge 
(magenta, sticks) and the C-terminal section of the 2,3-linker (electrostatic surface). Met752 and Gln753 
from the hinge loop are shown to be anchored by the residues from the 2,3-linker. (F) Ubiquitination assays 
of wild-type full-length WWP2 and the hinge loop mutants M752A, Q753A and M752T. The reactions were 





















Figure 34: Generation of fluorescein-labeled ubiquitin variant (UbF). (A) Sequence alignment of wild-type 
ubiquitin (WT-Ub) and ubiquitin variant (UbF1 and UbF2). The mutations: F4L, L8F, G10W, Q62K, K63M, 
E64G, T66S, H68Y, R74P and G76Q, and two extra residues at the C-terminus R77, I78 are introduced to 
make UbF1; Q2R, K6R, L8P, G10R, R42V, K48N, Q49R, Q62P, H68Y, V70F, L71M, G76L, and extra E77, 
N78 are introduced for UbF2. A S57C mutation is also performed to enable fluorescein labeling by cysteine 
alkylation. (B) Structure of UbF bound to the HECT domain of WWP1 (pdb accession: 5HPT). Ser57 was 
chosen to be mutated to cysteine for labeling because it is located in a flexible loop distant from the interface 
of UbF and HECT. (C) Schematic of the reaction showing labeling of the cysteine side-chain by reacting with 











4.3.4  Autoinhibitory mechanisms for other NEDD4 family members 
Given the high degree of sequence conservation of the 2,3-linker of WWP2 with 
that in WWP1 and ITCH (Figure 35A,B), we speculated that deletion of this linker would 
have a similar effect on these closely related E3 ligases.  Indeed, deletion of the 2,3-
linker from WWP1 and ITCH sharply increased their autoubiquitination activity as 
compared to the full-length proteins (Figure 35C,D).  These experiments indicate the 
functional conservation of the 2,3-linker as a key negative regulator among these highly 
homologous E3 ligases. 
 Like WWP2, NEDD4-1 also contains four WW domains (Figure 22 and Figure 
36A).  In comparison to WWP2, WWP1, and ITCH, however, NEDD4-1 shows no 
apparent sequence conservation of its WW2-WW3 linker with that of the WWP2, WWP1, 
and ITCH proteins, nor is it predicted to be α-helical (PSIPRED v3.3). Indeed, 
autoubiquitination activity of WW2-WW3 linker deleted NEDD4-1 showed nearly identical 
activity compared to full-length intact NEDD4-1 (Figure 36B). However, we hypothesized 
that a different segment of NEDD4-1 might play an analogous autoinhibitory role in 
NEDD4-1.  We therefore analyzed the predicted secondary structure of the domain 
linker segments within NEDD4-1 focusing on predicted α-helical regions. In this regard, 
the stretch of amino acids C-terminal to the WW1 domain (aa225-244) was selected as 
a potential regulatory motif based on its projected high probability as an α-helix 
(PSIPRED v3.3) and an established Thr phosphorylation (Thr229, Figure 36A) (203, 
204).   
 We generated NEDD4-1 containing this partial linker deletion (1,2-linker-deleted 
NEDD4-1) and showed that 1,2-linker deleted NEDD4-1 showed enhanced 








Figure 35: Sequence information for selected HECT E3 ligase regions and regulation of WWP1/ITCH by 2,3-
linker. (A) Sequence alignment of WWP2/WWP1/ITCH WW1-WW2-WW3-WW4-HECT sections showing the 
sequence identity. (B) Schematic diagram showing the architecture of WWP2, WWP1, and ITCH E3 ligases 
and the sequence alignment of the 2,3-linker region. WWP2, WWP1, and ITCH showed high sequence 
identity in the 2,3-linker region. Ubiquitination assay of (C) wild-type WWP1 and WWP1 with 2,3-linker 
deletion (WWP2 △2,3-linker) and (D) wild-type ITCH and ITCH with 2,3-linker deletion (ITCH △2,3-linker) 
















Figure 36: Autoinhibition of NEDD4-1. (A) Ubiquitination assay of wild-type NEDD4-1 and the △1,2-linker 
and △2,3-linker forms. The assay was carried out in same condition as Figure 24B, and quenched at time 
points indicated. (B) Schematic diagram showing the architecture of NEDD4-1. The predicted helix 
sequence (225-QDNLTDAENGNIQLQAQRAF-244) right after the WW1 domain is shown, with the threonine 
(T229) highlighted in red. (C) Ubiquitination assay of wild-type NEDD4-1, T229E NEDD4-1 and NEDD4-1 
with 1,2-linker deletion (WWP2 △1,2-linker). (D) Fluorescence anisotropy assay for UbF2 with NEDD4-1 
WW1-WW2-WW3-WW4-HECT and WW1-WW2-WW3-WW4-HECT with WW1,2-linker deletion. Two 












NEDD4-1 showed activity intermediate between 1,2-linker deleted and wt NEDD4-1 
(Figure 36C).  We also prepared a fluorescent ubiquitin variant (UbF2, Figure 34) 
selective for the NEDD4-1 exosite (69) and showed that it bound a 1,2-linker deleted 
form of NEDD4-1 ~5-fold more avidly than the corresponding NEDD4-1 with an intact 
1,2-linker (Figure 36D). These findings suggest that the regulatory linker module present 
in WWP2, WWP1, and ITCH is likely to be represented in NEDD4-1 and perhaps other 
HECT family members in diverse locations.  
 
4.4  Discussion 
Prior studies have suggested WW domain, C2 domain, and post-translational 
modification mediated autoinhibitory mechanisms for NEDD4 family HECT enzymes (50, 
82, 100, 137, 139, 142). The experiments in our study have identified an unanticipated 
mechanism of regulation of HECT domain E3. The centrally located WWP2 2,3-linker is 
highly conserved in the WWP1 and ITCH E3 ligases so it was unsurprising that WWP2, 
WWP1, and ITCH are similarly autoinhibited by this regulatory module.  It seems likely 
that an analogous autoinhibitory mechanism will extend to other HECT E3 ligases, given 
that NEDD4-1 which is a more weakly related enzyme to WWP2 shows similar behavior 
with deletion of a predicted linker helical module. Future work will be needed to 
investigate this possibility across the range of HECT family members. The form of 
regulation uncovered for WWP2, WWP1, ITCH, and NEDD4-1 is somewhat reminiscent 
of many proteases which exist as inactive pro-enzymes that are turned on by proteolytic 
removal of an autoinhibitory peptide segment (205), as well as the majority of protein 
tyrosine kinases that possess autoinhibitory loops that are stimulated by 
autophosphorylation (206).  The comparison to proteases is perhaps most relevant since 
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premature activation of proteases can lead to self-destruction prior to performing their 
necessary cellular jobs akin to what was observed for Δlinker WWP2.    
The crystal structure solved here greatly advanced our understanding of the 
molecular mechanism of linker mediated autoinhibition of HECT E3 ligases which 
involves locking the hinge loop and blocking ubiquitin exosite. While the hinge loop as a 
key regulatory structure of HECT is consistent with many previous studies(65, 67), the 
role of the exosite is more controversial. The results from several groups support the 
theory that the noncovalent ubiquitin adopted by the exosite serves as the acceptor of 
the ubiquitin at the active site, facilitating formation of poly-ubiquitin chains.(68, 72, 73) 
Recent studies indicate that the ubiquitin binding at exosite activates the ubiquitin 
transferase activity.(69, 76) Our study further supports the latter hypothesis. However, 
the mechanism of how the exosite ubiquitin binding could activate the HECT enzymatic 
activity remains elusive. One possible mechanism is that ubiquitin binding to the exosite 
leads to a conformational change, which enhances the flexibility of hinge loop or 
facilitates the ubiquitin transfer between E2, E3 and substrates, allosterically activating 
the HECT domain. It is also possible that the exosite plays distinct roles among different 
HECT E3 ligases. Further systematic and mechanistic studies are necessary to clarify 
the role of the exosite. Based on our structural study and others(76), the exosite seems 
to be a promising target for drug development that can regulate the activity of HECT E3 
ligases.     
 Although this study reveals the importance of the 2,3-linker in the catalytic 
regulation of WWP2, WWP1, and ITCH E3 ligases, it is likely that the C2 domain and 
WW domains participate in significant ways in impacting WWP2, WWP1, and ITCH 
functions including cellular localization or protein substrate targeting. It has previously 
been reported that the C2 domain autoinhibits WWP2 (137) which we did not observe 
112 
 
here.  However, the C2 domain likely still contributes to the autoinhibition of the 
SMURF2 and NEDD4-1 HECT ligases as proposed previously (137, 138). The role of 
the WW1-WW2 linker in NEDD4-1 appears to play a related role to the WW2-WW3 
linker in WWP2, although it appears not as quantitatively impactful to autoinhibition of 
NEDD4-1. Perhaps in the case of NEDD4-1, the C2 domain and WW1-WW2 linker 
synergize to autoinhibit NEDD4-1 catalytic activity. Future work should investigate the 
presumed complex interplay between the multiple mechanisms of regulating NEDD4 
family functions in normal and pathologic states to optimize the potential of therapeutic 





Chapter 5: Molecular Mechanism of Activation of Autoinhibited HECT E3 Ligases 
 
5.1  Introduction 
As discussed in Chapter 4, we demonstrated a new autoinhibitory mechanism for 
the HECT E3 ligase family beyond the previously proposed C2 and WW domain models. 
These autoinhibitory mechanisms ensure that the HECT enzymes are maintained in a 
relatively inactive state so that they only become activated in response to critical 
signaling events. It is therefore important to understand how these HECT E3 ligases are 
activated and regulated under physiologic conditions in the cell.  
One mechanism for the activation of autoinhibited HECT E3 ligases is the 
disruption of an intramolecular conformation by post-translational modifications which 
releases the HECT domain from its interactions with autoinhibitory domains. A 
previously reported example is that the tyrosine phosphorylation on the C2 domain and 
the HECT domain of NEDD4-1 leads to activation of ubiquitin transferase activity(140), 
which is proposed to relieve the autoinhibitory interaction between C2 domain and HECT 
domain(140). Another proposed mechanism of activation involves the competitive 
binding of substrates to the autoinhibitory domain, displacing it from binding the HECT 
domain(100). This is believed to happen in WW domain-mediated autoinhibition. The 
WW domains bind to the HECT domain through a weak WW-LPXY motif interaction, and 
in the presence of a substrate containing the PPXY motif, phosphorylated Ser/Thr and 
other high affinity structural features, the WW domain bound to the HECT domain could 
be replaced by protein substrates, leading to activation of the HECT E3 ligases(100).  
Since we discovered the linker as the autoinhibitory element which is not a 
canonical domain within HECT E3 ligases, it was interesting to investigate how the linker 
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mediated autoinhibition is regulated. It is notable that within the sequence of the WWP2 
linker, there are two conserved tyrosine residues that have been shown to be 
phosphorylated according to previous studies(142, 207, 208). Here, we report that the 
two tyrosine phosphorylation sites within the linker could stimulate the HECT E3’s 
enzyme activity, and structural and biochemical characterization indicates that these two 
phosphorylation sites employ different mechanisms for activation of the E3. We also 
investigate the functional effects of tyrosine phosphorylation of WWP2 in the cell using 
mutagenesis. 
 
5.2  Methods 
5.2.1  Plasmids and reagents 
OCT4 cDNA was from Dr. Izpisua Belmonte from Barcelona, Spain (209), and 
subcloned into pcDNA3.1 plasmid. Mutations and truncations in WWP2 were introduced 
by Quik-Change (Agilent). Purified wild-type ubiquitin, human ubiquitin-activating 
enzyme UBE1, and human ubiquitin-conjugating enzyme UbcH5c were prepared as 
described previously (188). The Colloidal Blue Staining Kit was purchased from 
Invitrogen. Anti-PTEN, anti-β-actin and anti-MYC antibodies were from Santa Cruz (CA, 
USA). Anti-OCT4 antibody was from Bethyl Laboratories (USA). Anti-NEDD4-2, anti-
AKT, anti-pAKT308 and anti-pAKT473 were from Cell Signaling Technologies (USA). 
Anti-ITCH antibody was from BD Biosciences (USA). Anti-phosphorylated tyrosine 
antibody (4G10) and the Dawson Dbz resin was from EMD Millipore (Germany). All 





5.2.2  Protein expression and purification 
BL-21 Codon Plus cells were transformed with the pGEX6p-2 plasmid expressing 
full-length WWP2 or the different mutations or truncations, initially as N-terminally 
modified GST-fusion proteins. The transformed cells were cultured in LB medium at 37 
°C to reach the optimal density (OD600=0.6) in a shaker incubator grown on a 1 L scale. 
Protein expression was induced by 0.25 to 0.5 mM IPTG at 16 °C for 20 hours. The cells 
were resuspended in 25 mL lysis buffer (25 mM Tris-HCl pH 8.0, 250 mM NaCl, 1 mM 
phenylmethylsulfonyl fluoride (PMSF) and 1x Roche cocktail protease inhibitors) and 
were lysed by french press. The cell lysate was loaded on glutathione agarose followed 
by washing with 25 mM Tris-HCl pH 8.0, 250 mM NaCl, and 0.1% Triton X-100. The 
desired GST-tagged protein was eluted using 10 mL 25 mM Tris-HCl pH 8.0, 250 mM 
NaCl containing 50 mM reduced glutathione at pH 8.0. The eluted fractions were 
combined and dialyzed against a buffer consisting of 25 mM Tris-HCl pH 8.0, 250 mM 
NaCl, 10 mM BME, and the protein was treated with PreScission protease at 4 °C 
overnight to cleave the GST tag. Afterwards, the mixture of GST and cleaved protein 
was loaded to glutathione agarose again to remove the GST. The protein was 
concentrated and then loaded on a size exclusion column Superdex 200 (GE 
Healthcare) with a buffer containing 25 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM DTT 
(dithiothreitol). The corresponding purified fractions assessed by Coomassie stained 
SDSPAGE were combined and glycerol was added to a final concentration of 10% v/v. 
The purified protein was concentrated to 1 to 10 mg/mL, flash frozen, and stored at -
80ºC. 
 
5.2.3  Peptide synthesis 
116 
 
The C-terminal thioester in  n-TTWQRPTAEYVRNpYEQWQ-c was generated 
using the Dawson’s Dbz resin (159). The peptide was synthesized manually using Fmoc 
solid phase synthesis. After assembling this peptide on the Dbz resin, the mixture was 
treated with p-nitrophenyl chloroformate and DIPEA to form C-terminal N-acyl-
benzimidazolinone (Dbz) followed by trifluoroacetic acid cleavage. The peptides were 
purified by reversed phase HPLC on a C-18 column using a water:acetonitrile gradient 
(containing 0.05% trifluoroacetic acid) to >90% and the correct structures confirmed by 
MALDI mass spectrometry (Figure 23) and amino acid analysis (AAA Service Laboratory 
Inc.). 
 
5.2.4  WWP2 semisynthesis 
To enable its ligation to the C-terminal thioester of the synthetic peptide n-
TTWQRPTAEYVRNpYEQWQ-c, the recombinant WWP2 protein fragment (aa 374-870) 
was generated containing an N-terminal Cys (S374C). As there was no Cys in a 
practical location for semisynthesis, we elected to perform a conservative replacement of 
a Cys for Ser374. Using QuikChange (Agilent) mutagenesis, the construct pGEX6p-2 
2,3-linker-WW3-WW4-HECT was modified to have a TEV protease site N-terminal to 
Cys374. The protein was expressed and purified in a similar way to other protein but 
using TEV protease instead of PreScission protease. During the FPLC purification step, 
the buffer used was 25 mM Tris-HCl pH 8.0, 150 mM NaCl, 1 mM TCEP 
(tricarboxyethyl-phosphine), to avoid DTT or BME (beta-mercaptoethanol). For the 
ligation reaction, about 1 mg of purified protein was mixed with 2 mM peptide in the 
buffer containing 75 mM HEPES pH 7.4, 400 mM MESNA, 1 mM TCEP, 10% glycerol in 
1 mL. The ligation reaction was allowed to proceed at room temperature for 24 hours, 
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followed by dialysis against buffer with 25 mM Tris-HCl pH7.5, 5 mM NaCl, 5 mM DTT, 
10% glycerol. The protein was then further purified by anion exchange chromatography 
using MonoQ column. The fractions containing purified semisynthetic pY369-2,3-linker-
WW3-WW4-HECT (aa356-870) were combined and concentrated to about 1 mg/mL. 
   
5.2.5  In vitro ubiquitination assays 
The in vitro ubiquitination reactions were carried out in microcentrifuge tubes in 
final volumes of 20 µL containing 40 mM Tris-HCl pH 7.5, 50 mM NaCl, 0.5 mM TCEP, 5 
mM MgCl2, with 5 mM ATP, 100 M ubiquitin, 50 nM E1 protein, 1 µM E2 protein, 1 µM 
E3 protein. The reactions were initiated by adding the E1 and carried out at 30 °C. At 
different time points, the reactions were quenched by mixing 4 µL aliquots of the reaction 
mixture with SDS loading dye and boiled for 5 minutes. The samples were then run out 
on SDSPAGE, and stained using a Colloidal Blue Staining Kit following the 
manufacturer’s protocol. The unmodified E3 protein bands at the time points shown in 
the figures were quantified using ImageJ densitometry and normalized to the zero time 
points.  Note that this quantification method monitors the disappearance of the 'starting 
material' but does not distinguish among the range of ubiquitinated products formed, and 
this product distribution pattern varies among different mutants. All assays were 
performed on at least two independent occasions with replicates showing similar results. 
 
5.2.6  Cell culture and Western blotting 
HeLa cells were seeded in 6-well plate, and transfected with 0.6 μg pcDNA3.1 
PTEN C124S (note that catalytically defective C124S PTEN was used because wt PTEN 
was toxic to cells under these conditions) and 0.3 μg pcDNA3.1 Myc-WWP2 using 
118 
 
Lipofectamine 3000 (Invitrogen) when the cell confluency reached 70-90%. For OCT4, 
the cells were transfected with 0.4 μg pcDNA3.1 OCT4, 0.5 μg pRK HA-ubiquitin, and 
0.6 μg pcDNA3.1 Myc-WWP2. 24 hours after transfection, the cells were lysed using 
RIPA buffer containing 1 mM PMSF and 1x Roche cocktail protease inhibitor. The lysate 
was mixed with SDS loading dye and boiled for 5 minutes. 30 μg of total protein (BCA 
assay) was subjected to SDSPAGE, and transferred to a nitrocellulose membrane using 
an iBlot dry blotting system (Thermo Fishier). The membranes were blocked with 5% 
BSA in TBST buffer for one hour, and then incubated with anti-PTEN antibody (1:50 
dilution) or anti-OCT4 antibody (1:500 dilution), anti-Myc antibody (1:100 dilution), and 
anti-actin antibody (1:8000 dilution) at 4 °C overnight. Afterwards, the membranes were 
washed with TBST and probed with HRP-conjugated anti-mouse secondary antibody at 
1:5000 dilution. The bands were detected by chemiluminescence using an ECL western 
blotting detection kit from GE Healthcare. All assays were repeated on at least two 
independent occasions with results and replicates showing similar results. 
 
5.2.7  Fluorescence microscopy 
To image fluorescent protein localizations in growing cells, HeLa cells were 
plated on eight-well chambered coverglasses (Lab-Tek, Thermo Scientific, Nunc), and 
when they reached 50% confluency, the cells were transfected with 50 ng pcDNA3.1 
GFP-WWP2 using lipofectamine 3000. Cells were also co-transfected with 5 μL of 
BacMam 2.0 expressing RFP tagged Lamp-1 (Thermo Fishier) as a lysosome marker. 
After 24 hours, cells were imaged with a 40×/1.3 oil objective on a Zeiss Observer.Z1 
inverted microscope. Images were acquired with GFP and RFP (where applicable) 
illumination using AxioVision software. These experiments were performed on 3 
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independent occasions and replicates gave consistent results. Classification of protein 
distribution across cells shown in Figure 41 was based on visual inspection from the 
combined replicates and based on examining at least 8 regions from the slides per 
WWP2 construct. 
 
5.2.8  CRISPR knockout of WWP2 in SHSY5Y cells 
 We designed the guide RNA using the gene editing tools at benchling.com. Two 
guide RNA sequences were selected with relatively high on-target and off-target scores, 
targeting Exon 2 (TCTGCCAGCTCTAGCCGGGC) and Exon 3 
(ACCTCGAATTAACTCCTACG). The constructs pSpCas9(BB)-2A-Puro-v2 carrying 
guide RNA sequence together with sgRNA and Cas9 protein were cloned following the 
protocol by Ran FA, et. al.(210) SHSY5Y neuroblastoma cells in 6-well plates with 70-
90% confluency were transfected with the two plasmids (0.75 µg each) using 
Lipofectamine 3000. 24 hours after transfection, cells were incubated with 1 µg/mL 
puromycin for 48 hours. Then the cells were seeded into 96-well plates using serial 
dilutions for the selection of single clones. After three weeks, the single clones were 
expanded and tested for WWP2 knockout using western blot.   
 
5.3  Results 
5.3.1  Activation of WWP2 by 2,3-linker tyrosine phosphorylation    
 We considered how the linker interactions in WWP2 might be regulated under 
physiological conditions. Interestingly, there are two tyrosine phosphorylation sites, 
Tyr369 and Tyr392, which have been mapped previously by mass spectrometry to the 
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linker region of WWP2 and are mostly conserved in WWP1 and ITCH (Figure 37A) (142, 
207, 208). We hypothesized that phosphorylation at one or both of these sites could 
influence WWP2 catalysis by disrupting interactions between the 2,3-linker and the 
HECT domain. Consistent with this, a pTyr369 containing synthetic 2,3-linker peptide 
was shown to be less potent as a WWP2 HECT domain inhibitor compared with the 
unmodified peptide (Figure 37B). To gain further insight into the role of pTyr369, we 
used protein semisynthesis (158) in the context of 2,3-linkerL-WW3-WW4-HECT WWP2 
(aa 356-870) to site-specifically install a pTyr residue at this position.  In this method, a 
synthetic peptide (aa 356-373) containing pTyr369 and a C-terminal thioester (159) is 
chemoselectively ligated to  an N-Cys containing WWP2 recombinant fragment (Figure 
38B,C) (157).  This ligation strategy introduces a Cys in place of Ser374, which was 
shown to be non-perturbing for WWP2 catalysis (Figure 38A).  The extended linker, 2,3-
linkerL, was selected for semisynthetic WWP2 construction since it incorporates the C- 
terminal residues of the WW2 domain that contribute to autoinhibition (Figure 31C,D and 
Figure 32A). 
 As expected, pTyr369-2,3-linkerL-WW3-WW4-HECT WWP2 was observed to 
have markedly enhanced autoubiquitination activity compared with non-phosphorylated 
control (Figure 38D). Although Glu is typically of limited reliability as a mimic of pTyr 
(157), analysis of the autoinhibited WWP2 crystal structure suggested that Glu 
replacement of Tyr369 or Tyr392 could be similarly disruptive as tyrosine 
phosphorylation to the linker-HECT interactions. Replacement of either Tyr369 or Tyr392 
with Glu as the single or double mutants in recombinant full-length WWP2 stimulated its 
autoubiquitination activity, although these Y/E mutants were still less active than full 2,3-
linker deletion (Figure 39A).  In addition to stimulating WWP2 autoubiquitination activity, 













Figure 37: Conserved Tyrosine phosphorylation sites in the WWP2 2,3-linkers and E3 ligase regulation, and 
their potential role to disrupt the autoinhibition. (A) Known tyrosine phosphorylation sites in 2,3-linker region 
of WWP2/WWP1/ITCH from phosphositeplus.com. (B) Ubiquitination assays of WWP2 △2,3-linker with 
different concentrations of 2,3-linker peptide with or without Tyr369 phosphorylation. Unphosphorylated 0, 
50 and 100 μM 2,3-linker peptide with natural sequence (2,3-linker peptide) or with phosphorylated Tyr369 



















Figure 38: Activation of WWP2 autoinhibition by Tyrosine 369 phosphorylation revealed by N-terminal 
expressed protein ligation. (A) Ubiquitination assay of wild-type or S374C mutant WWP2. Ser374 was 
mutated to cysteine for N-terminal native chemical ligation. Here the full-length recombinant WWP2 S374C 
mutant was assayed and its activity compared to wt WWP2. The reaction was performed as described in 
Figure 24B, and quenched at the indicated times. (B) Schematic diagram showing the strategy for 
semisynthesis of pY369-2,3-linkerL-WW3-WW4-HECT using so-called 'native chemical ligation.' The peptide 
(n-TTWQRPTAEYVRNpYEQWQ-c) with a C-terminal thioester was reacted with the purified recombinant 
WWP2 protein fragment aa374-870 possessing an N-terminal Cys S374C generating pY369-2,3-linkerL-
WW3-WW4-HECT protein (aa356-870). (C) Western blot of the non-phosphorylated (NP) and 
phosphorylated (pY369) 2,3-linkerL-WW3-WW4-HECT proteins using anti-phosphorylated tyrosine antibody 
(4G10). (D) Ubiquitination assays of non-phosphorylated (NP) and phosphorylated (pY369) 2,3-linkerL-
WW3-WW4-HECT. The reaction was conducted as described in Figure 24B, and quenched at the times 
indicated. 
  









using both coomassie staining and western blot (Figure 39B,C). In contrast, a tyrosine to 
phenylalanine mutation at Tyr369 or Tyr392 showed no appreciable effect (Figure 
39D,E). The crystal structure of WWP2 (Figure 40A,B,D) showed that Tyr369 contributes 
to the ubiquitin-binding exosite while Tyr392 sits on the hinge, indicating different roles 
for these two phospho-modifications. We tested the mechanistic impact of pTyr369 and 
pTyr392 on WWP2 by measuring the binding affinities of UbF1 for WW2-2,3-linker-
HECT Y369E and WW2-2,3-linker-HECT Y392E. These measurements showed that 
WW2-2,3-linker-HECT Y369E (UbF1 Kd of 0.86 µM) was much more available to 
ubiquitin binding at its exosite relative to WW2-2,3-linker-HECT Y392E (UbF1 Kd of 5.8 
µM) as predicted by the crystal structures (Figure 40).  These results establish distinct 
mechanisms of activation by the 2,3-linker tyrosine phosphorylation modifications at 
each end of the 2,3-linker. 
 
5.3.2  Cellular analysis of the role of the 2,3-linker in WWP2 regulation 
 Investigation of the cellular properties of WWP2 2,3-linker mutants using HeLa 
cell transfections showed that Myc-tagged full-length WWP2 containing a 2,3-linker 
deletion (ΔLinker) generated less WWP2 detectable by western blot than the wt WWP2 
protein (Figure 41A,B).  We hypothesized that such reduced WWP2 detection could be 
related to highly autoubiquitinated ΔLinker WWP2, which might be degraded or 
sequestered.  Consistent with these possibilities, ΔLinker WWP2 carrying a catalytically 
inactivating (C838S) mutation restored wild type WWP2 levels on western blot 
presumably because the autoubiquitination was eliminated (Figure 41A,B). 
 Live cell imaging demonstrated that GFP-tagged full-length ΔLinker WWP2 was 
co-localized with LAMP-1, the lysosomal marker, rather than showing the diffuse 
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Figure 39: Tyrosine to glutamate mutation activates WWP2 E3 ligase activity. (A) Ubiquitination assays of 
full-length wt WWP2 and the tyrosine to glutamate mutant forms (Y369E, Y392E, and Y369,392E). The 
reaction was carried out as described in Figure 24B and quenched at the times indicated. (C) Ubiquitination 
assays of full-length wt WWP2 and the tyrosine to glutamate mutant forms (Y369E, Y392E, and Y369, 
392E) and the 2,3-linker deleted form using PTEN as substrate. The reaction was carried out as described 
in Figure 24B with 5 μM PTEN, and quenched at the times indicated. (D) Immunoblot analysis of the 
ubiquitination assay in Figure 39C using PTEN antibody. (E) Ubiquitination assay of wt full-length WWP2 
and the Y369E and Y369F mutant forms. The assay was carried out as described in Figure 24B, and the 
reaction was quenched at 0, 0.5 and 2 hours. (F) Ubiquitination assay of wt full-length WWP2 and the 









           
 
                 
Figure 40: Structural mechanism for the Y369 and Y392 phosphorylation mediated activation of WWP2. (A) 
Overall structure of the WW2-2,3-linker-HECT protein superimposed with the UbV P2.3 structure. Local 
environments of Tyr369 (purple) and Tyr392 (blue) are highlighted by squares. (B) Zoom-in structure in the 
vicinity of Tyr369. Tyr369 (red, stick) appears to make pi-stacking interactions with the sidechains of Tyr365 
and Trp372 near the N-terminus of the 2,3-linker helix (red, cartoon). The HECT domain is shown as 
electrostatic surface (blue, red, and white). (C) Fluorescence anisotropy binding of UbF1 to WW2-2,3-linker-
HECT Y369E. (D) Zoom-in structure in the vicinity of Tyr392. (E) Fluorescence anisotropy binding of UbF1 
to WW2-2,3-linker-HECT Y392E. All the assays were repeated at least twice (n≥2) and shown good 
reproducibility.  
 A 
 B  C 
 D  E 
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distribution observed for wt GFP-WWP2 (Figure 41C).  This is compatible with previous 
findings that polyubiquitinated (K63) proteins can be targeted to lysosomes (80, 211). 
Experiments with C838S ΔLinker GFP-WWP2 revealed a wild-type WWP2-like cellular 
distribution, indicating a catalytic dependence for lysosomal localization of ΔLinker 
WWP2 (Figure 41C). These results highlight that unrestrained autoubiquitination activity 
could derail the E3 ligase from executing its normal functions. To test this idea, we 
performed co-transfections of WWP2 forms with the WWP2 substrate PTEN. In this 
experiment, it was found that wt full-length WWP2 reduced cellular PTEN protein, 
whereas ΔLinker WWP2 did not. The PTEN effects were reciprocal to WWP2 expression 
levels (Figure 42A,B) implying that uncontrolled, hyperactive WWP2 is disabled from 
targeting substrates because of self-destruction.  
 We also investigated the potential impact of WWP2 tyrosine phosphorylation in a 
cellular context with PTEN by transfecting HeLa cells with Myc-tagged full-length WWP2 
Y369E and Y369F. Y369E, Y369F, and wt WWP2 showed similar expression by western 
blot under these conditions (Figure 43A,B), suggesting that Y369E was more 
catalytically restrained than ΔLinker WWP2 which is consistent with the in vitro assays 
(Figure 39B). However, Y369E WWP2 transfection more powerfully reduced PTEN and 
OCT4 level than either wt or Y369F WWP2 (Figure 43A,B,C,D). To confirm that this 
PTEN protein level change is due to reduced protein stability, we treated transfected 
HeLa cells with cycloheximide (CHX) to block protein biosynthesis. These experiments 
showed that for up to 6 hours after CHX treatment, the WWP2 protein forms are fairly 
stable, but the PTEN level in Y369E WWP2 transfected cells showed significantly faster 
degradation than that in wt or Y369F WWP2 transfected cells (Figure 43E,F). The 
transfection of Myc-tagged full-length Y392E and Y392F WWP2 forms showed similar 







Figure 41: Expression and localization of WWP2 △2,3-linker in Hela cells. (A) Western blot analysis of 
WWP2 WT, WWP2 △2,3-linker, WWP2 △2,3-linker C838S in HeLa cells. HeLa cells were transfected with 
plasmids expressing N-terminally Myc-tagged full-length WWP2 forms: wild-type (WT), 2,3-linker deleted 
(△linker), and 2,3-linker deleted/C838S (△linker, C838S) for 24 hours, lysed, and analyzed by western blot 
using anti-Myc antibody and anti-actin antibody. (B) Quantification of WWP2 expression level. WWP2 and 
actin bands were quantified by densitometric analysis using Image J software. Relative WWP2 protein level 
was calculated by normalization with actin as loading control. (n=5, SEM shown). (C) Live-cell fluorescence 
analysis of WWP2 localization in HeLa cells. HeLa cells were transfected with plasmids expressing N-
terminally GFP-tagged full-length WWP2 forms: WT, △2,3-linker, and △2,3-linker/C838S, and co-
transfected with BamMam 2.0 (lysosome marker RFP-tagged LAMP-1) for 24 hours and then imaged. The 
GFP and RFP signals were analyzed and merged to show the localization of different WWP2s.  Shown are 
representative cells from WT (appearance of 40 out of 44 cells examined), △2,3-linker (appearance of 41 
out of 52 cells examined), and △2,3-linker/C838S (appearance of 30 out of 35 cells examined). 
  








    
 
 
Figure 42: Activity of WWP2 △2,3-linker on PTEN substrate in Hela cells. (A) Western blot analysis of 
WWP2 WT, WWP2 △2,3-linker, WWP2 △2,3-linker C838S in HeLa cells. HeLa cells were transfected with 
plasmids expressing N-terminally Myc-tagged full-length WWP2 forms: wild-type (WT), 2,3-linker deleted 
(△linker), and 2,3-linker deleted/C838S (△linker, C838S), and co-transfected with catalytically impaired 
PTEN (C124S) for 24 hours, lysed, and analyzed by western blot using anti-Myc antibody anti-PTEN 
antibody and anti-actin antibody. (B) Quantification of WWP2 and PTEN expression level. WWP2, PTEN 
and actin bands were quantified by densitometric analysis using Image J software. Relative WWP2 and 









       
       
 
 
Figure 43: Tyrosine 369 phosphorylation regulates WWP2 activity on PTEN and OCT4 substrates. (A) 
Western blot analysis of PTEN levels in HeLa cells transfected with N-terminally Myc-tagged WWP2 forms 
and co-transfected with PTEN (C124S). After 24 hours, cells were lysed and analyzed by western blot using 
anti-Myc, anti-PTEN and anti-actin antibodies. (B) Densitometry analysis of WWP2 and PTEN levels of data 
in Figure 43A. (n=4, SEM shown). (C) Western blot analysis of OCT4 levels in HeLa cells co-transfected 
with Myc-tagged WWP2 forms, HA-ubiquitin and OCT4.  After 24 hours, transfected cells were lysed and 
analyzed by western blot using anti-Myc, anti-OCT4 and anti-actin antibodies. (D) Densitometry analysis of 
OCT4 levels. (n=3, SEM shown). (E) HeLa cells transiently expressing PTEN were co-transfected without or 
with Myc-tagged wild-type WWP2, Y369E WWP2, or Y369F WWP2. 24 hours post-transfection, cells were 
treated with cycloheximide (CHX) for 0, 3, and 6 hours, lysed and analyzed by western blot. (n=3) (F) 
Densitometry quantification of the protein level change of PTEN after cycloheximide treatment in Figure 43E. 
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together, these results imply that 2,3-linker WWP2 phosphorylation has the potential to 
enhance WWP2-mediated protein substrate ubiquitination in cells.  
 
5.3.3  Genome-editing of WWP2 in SHSY5Y cells 
 The cellular studies above were dependent on transfection and overexpression, 
the results of which could be misleading. To gain further insights into the regulation of 
WWP2 in the cell, we employed the CRISPR/Cas9 based genome-editing technique to 
delete WWP2 in a cancer cell line. 
 We first tested the expression level of endogenous WWP2 and PTEN in different 
cell lines. As indicated by the western blot results (Figure 45A), among HEK293, HeLa, 
SHSY5Y and PC3, SHSY5Y has the highest expression of both WWP2 and PTEN. We 
thererfore chose the SHSY5Y neuroblastoma cell line to do the following CRISPR 
experiments.  
 Among 35 clones tested, there were at least five with undetectable WWP2 
expression (Figure 45B). Interestingly, for the knockout cells, there appeared a lower 
band detected by WWP2 antibody. We speculate that it is the transcript variant of 
WWP2 which does not contain the first five exons and the translational product is a 
truncated WWP2 without C2 domain. This WWP2 transcript variant has been reported to 
be involved in cell cycle regulation(212). Our result indicates that the expression of the 
truncated transcript variant increased after the knockout of full-length WWP2, probably 
through a compensation mechanism. Since the NEDD4 family members are closely 
related, we wondered whether the knockout of WWP2 would lead to increase of other 








Figure 44: Tyrosine 392 phosphorylation regulates WWP2 activity on PTEN substrate. (A) Western blot 
analysis of PTEN levels in HeLa cells transfected with N-terminally Myc-tagged WWP2 forms and co-
transfected with PTEN (C124S). After 24 hours, cells were lysed and analyzed by western blot using anti-








elevated compared to wild-type (Figure 45C). It remains to be investigated whether this 
increase is due to transcriptional activation or because other NEDD4 members are the 
substrates of WWP2. We also found that PTEN, as the canonical substrate of WWP2, 
was increased after WWP2 knockout. Increased PTEN typically leads to inactivation of 
the AKT signaling pathway, and indeed we also detected decreased AKT308 and 
AKT473 phosphorylation (Figure 45C).  
 At the time of writing this thesis, the ongoing work is focused on making the 
Y369E mutation in WWP2 gene in SHSY5Y cells using CRISPR. The goal is to 
introduce the mutation to mimic phosphorylation and generate endogenous WWP2 with 
activated ubiquitin transferase activity. With this model, we will be able to interrogate the 
biological roles of WWP2 phosphorylation and activation.  
  
5.4  Discussion   
 Although the precise signaling mechanisms remain to be elucidated, tyrosine 
phosphorylation of the 2,3-linker in WWP2 was shown to be a potential mechanism to 
relieve autoinhibition. That tyrosine phosphorylation takes place within an α-helical 
segment is notable, since tyrosine kinases generally bind substrate motifs in extended 
conformations (213).  We assume that when the linker dissociates from its 
intramolecular interactions with the HECT domain it would be flexible and can adopt a 
conformation suitable for kinase recognition. We found that the two different tyrosine 
phosphorylation sites confer distinct mechanisms to relieve autoinhibition (Figure 46).  
When the N-terminus of the 2,3-linker is phosphorylated, allosteric activation by ubiquitin 
is enabled (Figure 46).  When the C-terminus of the 2,3-linker is phosphorylated, 







Figure 45: CRISPR knockout of WWP2 in SHSY5Y cells. (A) Western blot analysis of WWP2 and PTEN 
levels in HeLa, HEK293, SHSY5Y and PC3 cells. (B) Western blot analysis of WWP2 expression for the 
clones after CRISPR knockout. *the sample from the clone in which WWP2 was not knocked out. (C) 







plausible that such compartmentalized activation mechanisms may drive specific 
biological outputs.  Prior work on ITCH suggested that the conserved 2,3-linker WWP2 
Tyr392 residue (Tyr371 in ITCH) is phosphorylated by Fyn tyrosine kinase leading to 
ITCH down-regulation (142).  However, this conclusion was based on a Tyr to Phe 
mutation (142) which is silent in WWP2 but may have partly relieved autoinhibition of the 
2,3-linker in the case of ITCH if the sidechain phenol is important for facilitating HECT 
interaction.  We believe that Tyr371 phosphorylation in ITCH is more likely to be 
activating based on the complete set of results for the close paralog WWP2 and the 
ITCH linker deletion results presented here.     
  It is noteworthy that several WWP2, WWP1, and ITCH cancer mutations fall in 
the 2,3-linker/HECT autoinhibited interface and such constitutive activation of these E3 
ligases may enhance tumor cell growth. Although more work will be needed to assess 
the precise contributions of these mutations to cancer, the degree of activation seen for 
these WWP2 cancer mutations in vitro are far lower than 2,3-linker deleted WWP2, 
which self-inactivated, but in the same range as the Y/E WWP2 mutations which led to 
PTEN reductions in our transfection experiments.  
 The tyrosine phosphorylation in the linker of ITCH has been shown to be 
catalyzed by Fyn, a Src tyrosine kinase(142). Nothing is known about the kinase for 
WWP2/WWP1 phosphorylation. It would be interesting to investigate the kinases that 
phosphorylate WWP2 Y369 and Y392, what signaling pathways they are involved in, 
and what biological functions they mediate. It is plausible that these two phosphorylation 
sites are catalyzed by different kinases and carry out distinct biological functions. It has 
been challenging for us to identify WWP2 Y369 phosphorylation in the cell lines I tested 
presumably due to the low abundance of WWP2 and probably low stoichiometry of 










Figure 46: Proposed model of HECT E3 ligase activation. The ground-state T-shape WWP2 (i) is 
autoinhibited but upon phosphorylation (ii), the 2,3-linker interactions with the hinge and the ubiquitin-binding 
exosite is loosened allowing ubiquitin to bind.  In (iii) E2-mediated ubiquitination of WWP2 takes place and 
protein substrate binds (the protein substrate can also be a separate WWP2 molecule).  In (iv) and (v) 
protein substrate mono- and poly-ubiquitination occurs.  After protein tyrosine phosphatase (PTPase) 







specific, or transient in response to certain signaling events. Another possibility is that 
the phosphorylated and activated WWP2 is not stable and gets degraded quickly. 
Overall, a better understanding of WWP2 phosphorylation under physiological and 
pathological conditions will be necessary for a full picture of the  biology of WWP2 and 
other HECT E3 ligases. 
In addition to phosphorylation, our data also suggests the potential role of 
dimerization/oligomerization in activating autoinhibited WWP2. Dimeric WWP2 and the 
aggregated form of WWP2 show higher activity than monomeric WWP2 (Figure 24 and 
Figure 25). How apparent dimer-induced activation of WWP2, described in Section 4, 
relates to the 2,3-linker remains to be determined but may provide yet another cellular 
mechanism to ensure a proper level of protein ubiquitin transfer activity.  
In summary, the internal linkers found between WW domains in 
WWP2/WWP1/ITCH/NEDD4-1 serve as a tunable brake for the regulation of ubiquitin 
transferase activity. Non-phosphorylated linker keeps the enzyme dormant, while 
phosphorylation or dimerization partially relieves the linker engagement and activates 
the ubiquitination activity. However, complete removal of the brake leads to 
hyperactivation and self-destruction (Figure 46). The structural and regulatory features 
discovered here should provide guidance to more detailed biological studies of these 













Figure 47: Proposed model of WWP2 regulation. The HECT domain of autoinhibited WWP2 is wrapped by 
the linker α-helix which blocks allosteric ubiquitin binding site (exosite) and constrains the hinge loop, locking 
the HECT domain in T-shape conformation. The activity of the HECT E3 ligase is inhibited so the substrate 
protein stays intact. Upon phosphorylation of the linker residues, the linker dissociates from the HECT 
domain, relieving the autoinhibition, so that it can catalyze the ubiquitin transfer and leads to ubiquitination 
and degradation of substrate protein. However, complete removal of linker causes hyperactivation and self-
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